AUTHOR INDEX

(P = proceedings)

ACHOLA, K. J. *see* AITKENHEAD, A. R.
ADAM, H. K. *see* SCOTT, M.
ADISS, G. J. *see* WHYTE, K. F.
ADVENIER, *see* BRION, N.
AITKENHEAD, A. R., LIN, E. S. & ACHOLA, K. J. The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers, 264
AKPAN, W. *see* NEUGEBAUER, G.
ALLEN, E. *see* MERCER, A.
ALLEN, G. D. *see* GILL, T. S.
ALLEN, S. *see* WOODWARD, S. A.
ALLISON, N. L. *see* ZIEMNIAK, J. A.
AL-SEREITI, M. R. & TURNER, P. The effect of a single oral dose of lisuride, terguride and bromocriptine on intraocular pressure, 122P
AL-SEREITI, M. R., COAKES, R. L., O'SULLIVAN, D. P. D. & TURNER, P. A comparative study of the effect of timolol and bromocriptine eye drops on intraocular pressure in healthy volunteers, 681P
AL-WAIZ, M. *see* AYESH, R.
ANDREW, P. *see* THOMAS, M.
ANGLE, S. G. *see* HUNTER, K. R.
ANKIER, S. I. *see* WARRINGTON, S. J.
ANKIER, S. I., MEKKI, Q. A. & WARRINGTON, S. J. Pharmacodynamic effects of single and repeated doses of two formulations of trazodone, 135P
ARANKO, K. *see* MATTILA, M. J.
ARIAS, T. D. *see* INABA, T.
ARNOLD, B. D. C. *see* COOPER, S. M.
ARNOLD, B. D. C., COOPER, S. M. & RAPEPORT, W. G. An investigation of 5-hydroxytryptamine induced axon reflex flares in man, 126P
ARNOUT, J., VAN HECKEN, A., DE LEPELEIRE, I., MIYAMOTO, Y., HOLMES, I., DE SCHEPPER, P. & VERMYLEN, J. Effectiveness and tolerability of CV-3988, a selective PAF antagonist, after intravenous administration to man, 445
ARONSON, J. K. *see* WOOD, A. J.
ATANGA, G. K. *see* FOSTER, R. W.
ATKINSON, H. C. & BEGG, E. J. Prediction of drug concentrations in human skim milk from plasma protein binding and acid-base characteristics, 495
AVENANT, J. C. *see* MEYER, E. C.
AYESH, R., DAWLING, S., WIDDOP, B., IDLE, J. R. & SMITH, R. L. Influence of quindine on the pharmacokinetics of nortriptyline and desipramine in man, 140P
AYESH, R., SCADDING, G., BROSTOFF, J. IDLE, J. & SMITH, R. L. Stability of the debrisoquine metabolic ratio to immunoperturbation by influenza and pneumococcus vaccines, 141P
AYESH, R., AL-WAIZ, M., MCBURNEY, A., MITCHELL, S. C., IDLE, J. R., WARD, J. W. & SMITH, R. L. Variable pinacidil *N*-oxidation: lack of correlation with the debrisoquine and trimethylamine oxidation polymorphisms, 142P
AYESH, R., MITCHELL, S. C., WARING, R. H. & SMITH, R. L. Taste sensitivity to phenylthiourea: lack of correlation with the debrisoquine and carboxymethylcysteine oxidation polymorphisms, 664P
AYESH, R., AL-WAIZ, M., CROTHERS, M. J., CHOLERTON, S., MITCHELL, S. C., IDLE, J. R. & SMITH, R. L. Deficient nicotine *N*-oxidation in two sisters with trimethylaminuria, 664P

BACK, D. J. *see* BALL, S.
BACK, D. J., GRIMMER, S. F. M., ORME, M. L. E., PROUDLOVE, C., MANN, R. D. & BRECKENRIDGE, A. M. Evaluation of committee on safety of medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics, 527
BACK, D. J., MADDEN, S. & MARTIN, C. A. Presystemic metabolism of the oral contraceptive steroid desogestrel, 675P
BAILEY, R. R., WALKER, R. J., LYNN, K. L., DONALDSON, I.MCG., PEDDIE, B. A. & DOBBS, B. R. Intravenous enoxacin for the treatment of acute pyelonephritis: pharmacokinetic and clinical study, 223
BAILLIE, S. P., QUINN, K., BATEMAN, D. N. & WOODHOUSE, K. W. Age and morphine pharmacokinetics after intravenous, oral and slow release morphine sulphate, 133P
BAIRD, A., HAMILTON, T. C., RICHARDS, D. H., TASKER, T. & WILLIAMS, A. J. Inhibition of histamine induced bronchoconstriction in normal healthy volunteers by a potassium channel activator, cromakalim, BRL 34915, 114P
BAIRD-LAMBERT, J. A. *see* GROSS, A. S.
BAKRAN, A. *see* GUPTA, S. K.
BALL, S., BACK, D. J. & ORME L'E. Characterisation and inhibition of oestrogen 2-hydroxylase activity in human liver microsomes, 643P
BALL, S. G. *see* HERRICK, A. L.
BALLANTYNE, D. *see* NORTHCOTE, R. J.
BANIM, S. O. *see* DEBBAS, N. M. G.
BAR, R. M., KOBZA BLACK, A., DOWD, P. M., KORO, O., MISTRY, K., ISAACS, J. L. & GREAVES, M. W. The *in vitro* 5-lipoxygenase and cyclo-oxygenase inhibitor L-652,343 does not inhibit 5-lipoxygenase *in vivo* in human skin, 23
BARBER, C. *see* SWIRE, F. M. M.
BARNES, N. C. *see* EVANS, J. M.
BARNES, P. J. *see* BLACK, P. N.
BARNES, P. J. *see* EVANS, T. W.
BARNES, T. S. *see* MURRAY, G. I.
BARNETT, D. B. *see* WALLEY, T. J.
BARR, S. M., FULTON, J. D., MCBRYAN, D. D., REID, J., BUTTERS, L., LEES, K. R., HAMILTON, C. A. & REID, J. L. The effect of age on platelet intracellular free calcium concentration, 658P
BARRATT, L. J. *see* ROBSON, R. A.

BARRY, H. *see* O'BOYLE, C. A.
BARRY, M. *see* MACMUTHANA, P.
BASTAIN, W. *see* SCOTT, A. K.
BATEMAN, D. N. *see* BAILLIE, S. P.
BATEMAN, D. N. *see* RODGERS, A.
BAX, D. E. *see* BAX, N. D. S.
BAX, N. D. S., RICHARDS, R. K., WODDS, H. S., WOODS, H. F. & BAX, D. E. Adverse drug reactions in elderly patients in hospital, 94P
BEASLEY, R. *see* MISKIEL, K. A.
BEASLEY, R., RAFFERTY, P. & HOLGATE, S. T. Adverse reactions to the non-drug constituents of nebuliser solutions, 283
BEAUMONT, D., *see* BRION, N.
BECK, T. R. *see* ZIEMNIAK, J. A.
BEGG, E. J. *see* ATKINSON, H. C.
BELLETT, M. & MÉNARD, J. Counter-regulatory effects of combined ACE-inhibition and calcium antagonism, 526
BELPAIRE, F. M. *see* FRAEYMAN, N. F.
BENNETT, P. N. *see* FORDYCE, K. S.
BENNETT, P. N., NOTARIANNI, L. J., CAIN, A. R. R., DUNSTER, G. D., HUMPHRIES, S. J., MARRIOTT, B. A., MURRAY, S., OSBORNE, J. P., RECKLESS, J. P. D. & RUDD, P. T. Carbimazole and breast feeding: milk concentrations and effects on infant thyroid function, 642P
BENVENISTE, J. *see* POITEVIN, B.
BENZONI, D. *see* FERRY, N.
BERGGREN, L. *see* SUNZEL, M.
BERKIN, K. E. *see* HERRICK, A. L.
BERLAN, M. *see* GALITZKY, J.
BERNARD, R. *see* WALTER, M.
BERTILSSON, L. *see* EICHELBAUM, M.
BERTILSSON, L. *see* PISANI, F.
BEWLEY, A. *see* O'BOYLE, C. A.
BHAMRA, R. *see* HENRY, J. A.
BING, R. F. *see* WALLEY, T. J.
BINS, J. W. & MATTIE, H. Saturation of the tubular excretion of β-lactam antibiotics, 41
BIRD, H. A. *see* PULLAR, T.
BIRKETT, D. J. *see* ROBSON, R. A.
BIRMINGHAM, A. T. *see* SWIRE, F. M. M.
BIRTWELL, A. J. *see* PULLAR, T.
BIRTWELL, J. *see* OWENS, D. R.
BLACK, P. N. *see* FULLER, R. W.
BLACK, P. N., FULLER, R. W., TAYLOR, G. W., BARNES, P. J. & DOLLERY, C. T. Bronchial reactivity is not increased after inhalation of leukotriene B_4 and prostaglandin D_4, 667P
BLACKBURN, M. *see* CHOONARA, I. A.
BLACKETT, A. *see* CHIJIOKE, P. C.
BLAUW, G. J., VAN BRUMMELEN, P., VERMEY, P. & VAN ZWIETEN, P. A. Direct and indirect vascular effects of serotonin in man, 629P
BLYDEN, G. T. *see* SCAVONE, J. M.
BOCHSLER, J. A., SIMMONS, R., WARD, P. J., CHESTER, P. & LATHAM, A. N. Double-blind evaluation of sustained release verapamil and long acting propranolol in hypertensive patients, 100P
BOLOGNESE, J. A. *see* CIRILLO, V. J.
BONATI, M., TRAINA, G. L., GENTILE, M. G., FELLIN, G., ROSINA, R., CAVENAGHI, L. & BUNIVA, G. Pharmacokinetics of intraperitoneal teicoplanin in patients with chronic renal failure on continuous ambulatory peritoneal dialysis, 761
BONDESEN, S., BRØNNUMSCHOU, J., PEDERSEN, V., RAFIOLSADAT, Z., HONORÉ HANSEN, S. & HVIDBERG, E. F. Absorption of 5-aminosalicylic acid from colon and rectum, 269
BOOBIS, A. R. *see* KOBAYASHI, S.
BOOBIS, A. R. *see* ZHI-GUANG, T.
BOPPANA, V. K. *see* ZIEMNIAK, J. A.
BOWDLER, D. A. *see* HOLLING, J. D.
BOYLE, R. *see* WOODWARD, S. A.
BRANDMAN, S., CLARKE, M. ROYCHOUDHURY, D., JUBBER, A., DEWS, I., STEPHENS, J. & VANDENBURG, M. Efficacy of metoprolol oros compared with conventional metoprolol in extending the exercise tolerance of patients with angina pectoris, 153P
BREARLEY, C. J. *see* WOOD, A. J.
BRECKENRIDGE, A. An appreciation, 281
BRECKENRIDGE, A. M. *see* BACK, D. J.
BRECKENRIDGE, A. M. *see* CHRISTIE, G.
BRECKENRIDGE, A. M. *see* ROBERTS, D. H.
BREIMER, D. D. *see* SOONS, P. A.
BREIMER, D. D. *see* VAN HARTEN, J.
BRENDEL, E. *see* DE MEY, C.
BRENTH, B. F. H. *see* FEITSMA, K. G.
BREWERTON, D. A. *see* DIXEY, J. J.
BRION, N., BEAUMONT, D. & ADVENIER, C. Evaluation of the antimuscarinic activity of atropine, terfenadine and mequitazine in healthy volunteers, 27
BRITTEN, A. *see* RICHARDS, R.
BRITTON, J. R. *see* KNOX, A. J.
BRODIE, M. J. *see* GILLHAM, R. A.
BRODIE, M. J. *see* LARKIN, J. G.
BRODIE, M. J. *see* MACPHEE, G. J. A.
BRODIE, M. J. *see* MCINNES, G. T.
BRØNNUMSCHOU, J. *see* BONDESEN, S.
BROSTOFF, J. *see* AYESH, R.
BROWN, J. *see* JEFFREY, R. F.
BROWN, K. F. *see* GROSS, A. S.
BROWN, M. J., LOYSEN, E. & MORICE, A. H. Non-invasive measurement of skin blood flow: value as index of post-synaptic α_2-adrenoceptor stimulation in man, 631P
BULPITT, C. J. *see* HAWKINS, C. M. A.
BUNIVA, G. *see* BONATI, M.
BURCKART, G. J. *see* MEHTA, M. U.
BURKE, M. D. *see* MURRAY, G. I.
BUSH, A., BUSST, C. M., MILLAR, A. & SYRETT, N. Time course of the effects of epoprostenol on effective pulmonary blood flow in normal volunteers, 341
BUSST, C. M. *see* BUSH, A.
BUTLER, E. *see* GILLHAM, R. A.
BUTTERS, L. *see* BARR, S. M.

CAIN, A. R. R. *see* BENNETT, P. N.
CALDWELL, J. *see* HOTCHKISS, S. A.
CALLANDER, J. S. *see* HERRICK, A. L.
CAMERON, H. A., WALLER, P. C. & RAMSAY, P. C. & RAMSAY, L. E. Lessons from twenty years of drug trials in intermittent claudication, 653P
CAMM, A. J. *see* DEBBAS, N. M. G.

CAMPBELL, J. *see* HOLDING, J. D.
CARMODY, M. *see* KELLY, J. G.
CASTLEDEN, C. M. *see* SCOTT, M.
CAVENAGHI, L. *see* BONATI, M.
CHALLENOR, V. *see* RENWICK, A. G.
CHALLENOR, V. F. *see* FRANCIS, J. L.
CHALLENOR, V. F., WALLER, D. G., RENWICK, A. G. & GEORGE, C. F. Sustained-release nifedipine for chronic stable angina pectoris, 640P
CHALMERS, D. & LAWSON, D. H. Post marketing surveillance of captopril—a reply, 782
CHANG, P. C., KRIEK, E., VAN DER KROGT, J. A., VERMEIJ, P. & VAN BRUMMELEN, P. Stimulation of noradrenaline release by peripheral presynaptic β-adrenoceptors, 649P
CHAPUT DE SAINTONGE, D. M. *see* RUST, N. D.
CHATLANI, P. T. *see* ROBERT, D. H.
CHAUDHURY, P. R. *see* SCOTT, A. K.
CHELLINGSWORTH, M. C. & KENDALL, M. J. Effects of nifedipine, verapamil and diltiazem on renal function, 599
CHESTER, P. *see* BOCHSLER, J. A.
CHIJIOKE, C. P., PEARSON, R. M., JOHNSTON, A. & BLACKETT, A. Effect of acipimox on plasma digoxin levels in elderly patient volunteers, 102P
CHIJIOKE, C. P., GILLIAM, M. & PEARSON, R. M. Effect of (±)-propranolol and caffeine on human sperm motility using a modified trans-membrane migration technique, 620P
CHOLERTON, S. *see* AYESH, R.
CHOLERTON, S. *see* CHOONARA, I. A.
CHOONARA, I. A., MALIA, R. G., HAYNES, B. P., HAY, C. R., COLERTON, S., BRECKENRIDGE, A. M., PRESTON, F. E. & PARK, B. K. The relationship between inhibition of vitamin $K_{1\ 2,3}$-epoxide reductase and reduction of clotting factor activity with warfarin, 1
CHOONARA, I. A., WHEELDON, J., RAYNER, P., BLACKBURN, M. & LEWIS, I. J. Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia, 622P
CHRISTIE, G., COLEMAN, J. W., NEWBY, S., MCDIARMAID-GORDON, A., HAMPSON, J. P., BRECKENRIDGE, A. M. & PARK, B. K. A survey of the prevalence of penicillin-specific IgG, IgM and IgE antibodies detected by ELISA and defined by hapten inhibition in patients with suspected penicillin allergy and in healthy volunteers, 381
CIRILLO, V. J., GOMEZ, H. J., SALONEN, J., SALONEN, R., RISSANEN, V., BOLOGNESE, J. A., NYBERG, R. & KRISTIANSON, K. Lisinopril: Dose-peak effect relationship in essential hypertension, 533
CLARK, R. A. *see* LIPWORTH, B. J.
CLARKE, B. *see* EVANS, T. W.
CLARKE, M. *see* BRANDMAN, S.
CLARKSON, A. *see* ZUSSMAN, B. D.
CLARKSON, A., COATES, P. E. & ZUSSMAN, B. D. A specific h.p.l.c. method for the determination of BRL 43694 in plasma and urine, 136P
CLAUSEN, T. G., WOLFF, J., HANSEN, P. B., LARSEN, F., RASMUSSEN, S. N., DIXON, J. S. & CREVOISIER, C. Pharmacokinetics of midazolam and α-hydroxymidazolam following rectal and intravenous administration, 457
CLYBURN, P. A. *see* MOUSDALE, S.
COAKES, R. L. *see* AL-SEREITI, M. R.
COATES, P. E. *see* CLARKSON, A.
COATES, P. E. *see* ZUSSMAN, B. D.
COCHRANE, G. M. *see* HORN, C. R.
COLEMAN, J. W. *see* CHRISTIE, G.
COLEMAN, R. L. *see* JUPE, D. M. L.
COLLIER, P. S. *see* FEE, J. P. H.
COLLINS, W. *see* O'CONNOR, P.
CONRADSON, T-B. *see* EVANS, T. W.
CONWAY, E. I. *see* JACKSON, B.
COOPER, R. G., STOKES, M. J., EWARDS, R. H. T. & STARK, R. D. Absence of excess peripheral muscle fatigue during β-adrenoceptor blockade, 405
COOPER, S. M. *see* ARNOLD, B. D. C.
COOPER, S. M. *see* RAPEPORT, W. C.
COOPER, S. M., ARNOLD, B. D. C. & RAPEPORT, W. G. Inhibition of 5-HT induced axon-reflex flares by BRL43694, a novel 5-HT_3 receptor antagonist, 106P
COOPER, W. D. *see* KELLY, J. G.
COPELAND, S., MILLIGAN, J. G. L., HARRON, D. W. G. & RIDDELL, J. G. The effects of diltiazem on the affinity, density and function of human lymphocyte β-adrenoceptors, 660P
CORBETT, R. *see* STANIFORTH, D. H.
CORRIS, P. A. *see* GILMARTIN, J. J.
COSTELLO, J. F. *see* EVANS, J. M.
COULSON, R. R. *see* MACCLEAN, D.
COURT, E. N. *see* STENTON, S. C.
COWEN, P. J. *see* SOLOMON, R. A.
COWIE, J. *see* MCAUSLANE, J. A. N.
CRANNY, A. *see* O'CONNOR, P.
CREVOISIER, C. *see* CLAUSEN, T. G.
CROTHERS, M. J. *see* AYESH, R.
CUBELA, R. B. *see* JACKSON, B.
CUISINAUD, G. *see* FERRY, N.
CULLEN, M. *see* O'CONNOR, P.
CURRIE, D. *see* NICHOLSON, A. N.
CURRIE, D., LEWIS, R., MCDEVITT, D. G., NICHOLSON, A. N. & WRIGHT, N. A. Central effects of the β-adrenoceptor antagonists propranolol and atenolol, 124P
CYRONAK, M. J. *see* ZIEMNIAK, J. A.

D'HEYGERE, F., LING, T., WADDELL, G., HARLOW, B. JAMES, I. & MCINTYRE, N. Evaluation of steady state plasma levels of nicardipine hydrochloride in patients with impaired liver function, 96P
DANHOF, M. *see* VAN HARTEN, J.
DAVENAS, E. *see* POITEVIN, B.
DAVIES, A. J. *see* EDWARDS, G.
DAVIES, B. E. *see* GILL, T. S.
DAVIES, B. E., DIERDORF, D., ECKL, K. M., GREB, W. H., MELLOWS, G. & THOMSEN, T. The pharmacokinetics of cromakalim, BRL 34915, a new antihypertensive agent, in healthy male subjects, 136P
DAVIES, D. S. *see* ZHI-GUANG, T.
DAVIES, J. A. *see* HAIGH, J. R. M.
DAWLING, S. *see* AYESH, R.
DEBBAS, N. M. G., JOHNSTON, A., JACKSON, S. H. D.,

BANIM, S. O., CAMM, J. & TURNER, P. The effect of nitrendipine on predose digoxin serum concentration, 151P
DE BOER, A. G. *see* SOONS, P. A.
DEERING, A. H. *see* HARRON, D. W.
DEERING, A. H. *see* KONDOWE, G. B.
DEERING, A. H., RIDDELL, J. G., HARRON, D. W. G. & SHANKS, R. G. Effect of acute and chronic oral administration of alfuzosin on baroreflex function and tremor in man, 417
DELAMOS, B. *see* MEHTA, M. U.
DE LEPELEIRE, I. *see* ARNOUT, J.
DELLA CORTE, L. *see* SGARAGLI, G. P.
DELLO, C. D. *see* FRAEYMAN, N. F.
DE MEIRLERI, K. *see* DUPONT, A. G.
DE MEY, C., BRENDEL, E., ENTERLING, D. & WESCHE, H. Slow dissolution characteristics *in vitro* do not necessarily imply slow and sustained release behaviour *in vivo*, 139P
DE MEY, C. & ENTERLING, D. Limitations in the non-invasive assessment of the cardiovascular changes induced by repeated doses of atropine in normal man, 647P
DE SCHEPPER, P. *see* ARNOUT, J.
DE VANE, P. J. *see* THOMPSON, A. H.
DEWS, I. *see* BRANDMAN, S.
DEWS, I. *see* WOODWARD, S. A.
DE ZEEUW, R. A. *see* FEITSMA, K. G.
DHILLON, D. P. *see* LIPWORTH, B. J.
DIERDORF, D. *see* DAVIES, B. E.
DIXEY, J. J., NOORMOHAMED, F. H., LANT, A. F. & BREWERTON, D. A. Effect of maximal hydration on the renal responses to pretreatment with non-steroidal anti-inflammatory drugs and probenecid in man, 614
DIXON, C. M. *see* EVANS, T. W.
DIXON, J. S. *see* CLAUSEN, T. G.
DIXON, J. S. *see* PULLAR, T.
DOBBS, B. R. *see* BAILEY, R. R.
DOLLERY, C. T. *see* BLACK, P. N.
DOLLERY, C. T. *see* FULLER, R. W.
DONALDSON, I. MCG. *see* BAILEY, R. R.
DONNELLY, R., ELLIOTT, H. L., MEREDITH, P. A. & REID, J. L. Ketanserin in essential hypertension: individual response and concentration-effect relationships, 103P
DONNELLY, R., ELLIOTT, H. L. & MEREDITH, P. A. Counter-regulatory effects of combined ACE inhibition and calcium antagonism, 525
DONNELLY, R., ELLIOTT, H. L., MEREDITH, P. A. & REID, J. L. Vascular pressor responses in treated and untreated essential hypertension, 652P
DORRELL, L. *see* HILLIER, K.
DOW, R. J. *see* MACCLEAN, D.
DOW, R. J. *see* MACDONALD, F. C.
DOWD, P. M., *see* BARR, R. M.
DOYLE, G. D. *see* KELLY, J. G.
DRESSE, A. *see* WALTER, M.
DUBB, J. W. *see* ZIEMNIAK, J. A.
DUCHIN, K. L. *see* SINGHVI, S. M.
DULIE, E. *see* MCVEIGH, G. E.
DUNDEE, J. W. *see* FEE, J. P. H.
DUNDEE, J. W. *see* FLYNN, R. J.
DUNDEE, J. W. *see* MILLIGAN, K. R.
DUNDEE, J. W., GHALY, R. G. & FITZPATRICK, K. T. J. Randomised comparison of the antiemetic effects of metoclopramide and electro-acupuncture in cancer chemotherapy, 678P
DUNDEE, J. W., FITZPATRICK, K. T. J., GHALY, R. G. & PATTERSON, C. C. Does dextrality or sinistrality affect the outcome of P6 acupuncture anti-emesis?, 679P
DUNSTER, G. D. *see* BENNET, P. N.
DUPONT, A. G., DE MEIRLEIR, K., VAN DER NIEPEN, P. & SIX, R. O. Renal haemodynamic and blood pressure lowering effects of flosequinan, 149P
DUTTON, M. *see* MACPHEE, G. J. A.
DWYER, R. *see* FLYNN, R. J.

ECKL, K. M. *see* DAVIES, B. E.
EDWARDS, G., LOOAREESUWAN, S., DAVIES, A. J., WATTANAGOON, Y., PHILLIPS, R. E. & WARRELL, D. A. Pharmacokinetics of chloroquine in Thais: Plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with *Plasmodium vivax* malaria, 477
EDWARDS, R. H. T. *see* COOPER, R. G.
EICHELBAUM, M., BERTILSSON, L., KÜPFER, A., STEINER, E. & MEESE, C. O. Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine, 505
ELBORN, J. S., NICHOLLS, D. P. & STANFORD, C. F. Flosequinan in chronic cardiac failure, 635P
ELLIOTT, H. L. *see* DONNELLY, R.
ELLIOTT, H. L. *see* SCHAFERS, R. G.
ELLIOTT, H. L. *see* SUMNER, D. J.
ENTERLING, D. *see* DE MEY, C.
ERIKSSON, I. *see* SUNZEL, M.
ESSEX, E. *see* HORN, C. R.
EVANS, J. M. *see* SILKE, B.
EVANS, J. M., BARNES, N. C., PIPER, P. J. & COSTELLO, J. F. The effect of REV 5901 on histamine and leukotriene D_4 induced bronchoconstriction in man, 111P
EVANS, J. M., BARNES, N. C., PIPER, P. J. & COSTELLO, J. F. The effect of a single dose of inhaled L-648,051, a leukotriene D_4 antagonist, in mild asthma, 112P
EVANS, T. W., DIXON, C. M., CLARKE, B., CONRADSON, T-B. & BARNES, P. J. Comparison of neurokinin A and substance P on cardiovascular and airway function in man, 273
EVERETT, D. W. *see* SINGHVI, S. M.
EWEN, S. W. B. *see* MURRAY, G. I.

FACCHINI, V. *see* KILBY, P.
FAEGRI, A. *see* MATHESON, I.
FAMILIAR, R. G. *see* ZIEMNIAK, J. A.
FAZIO, A. *see* PISANI, F.
FEE, J. P. H., FURNESS, G., MCCOLLUM, J. S. C., COLLIER, P. S. & DUNDEE, J. W. Single induction doses of thiopentone, propofol and midazolam do not cause enzyme induction in man, 140P
FEELY, J. *see* MACMUTHANA, P.
FEELY, J. *see* O'CONNOR, P.
FEELY, M. *see* HAIGH, J. R. M.
FEELY, M. P. *see* PULLAR, T.

FEHER, M. D. *see* OATES, N. S.
FEINBERG, G. *see* STOKES, T. C.
FEITSMA, K. G., POSTMA, D. S., KOËTER, G. H., NOSSENT, G. D., BRENTH, B. F. H., & DE ZEEUW, R. A. Comparative study of the bronchodilating effects of (–)- and (+)-oxyphenonium bromide, 683
FELLIN, G. *see* BONATI, M.
FERNER, R. E., WILSON, D. & RAWLINS, M. D. Angiotensin converting enzyme inhibition potentiates the effects of intradermal bradykinin in hypertensive patients 105P
FERRY, N., GEOFFROY, J., POZET, N., CUISINAUD, G., BENZONI, D., ZECH, P. Y. & SASSARD, J. Influence of renal insufficiency on the pharmacokinetics of cicletanine and its effects on the urinary excretion of electrolytes and prostanoids, 359
FINDLAY, J. G. *see* HERRICK, A. L.
FISCHER, C. *see* HANDEL, J.
FITSCHA, P. *see* SINZINGER, H.
FITZPATRICK, K. T. J. *see* DUNDEE, J. W.
FITZSIMONS, T. J. *see* MACLEAN, D.
FITZSIMONS, T. J. *see* SCOTT, M.
FLETCHER, A. E. *see* HAWKINS, C. M. A.
FLYNN, R. J., MCMURRAY, T. J., MOORE, J., DWYER, R. & DUNDEE, J. W. Comparison of plasma concentrations following epidural infusion of 0.08% and 0.25% bupivacaine during labour, 109P
FOLEY, B. *see* MACMUTHANA, P.
FORDYCE, K. C., NOTATIANNI, L. J. & BENNETT, P. N. Genetic and environmental influences on salicylate metabolism, 95P
FORSTER, J. K. *see* MACONOCHIE, J. G.
FORSYTH, D. R. & ROBERTS, C. J. C. Nitrendipine natriuresis: a tubular site of action?, 662P
FORSYTH, D. R., JAYASINGHE, K. S. A. & ROBERTS, C. J. C. Study of the potential pharmacokinetic interaction between nizatidine, cimetidine and ibuprofen in man, 672P
FOSTER, R. W. & ATANGA, G. K. Bronchodilator drug bioassay by whole body plethysmography in the normal human subject, 113P
FOWLER, C. *see* RICHARDS, R.
FOWLER, P. *see* MACONOCHIE, J. G.
FOX, E. *see* O'BOYLE, C. A.
FRAENKEL, M. *see* ROBSON, R. A.
FRAEYMAN, N. F., DELLO, C. D. & BELPAIRE, F. M. α_1-acid glycoprotein concentration and molecular heterogeneity: relationship to oxprenolol binding in serum from healthy volunteers and patients with lung carcinoma or cirrhosis, 733
FRANCIS, J. L., ROATH, O. S., CHALLENOR, V. F. & WALLER, D. G. The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon, 751
FRANTZ, M. *see* SINGHVI, S. M.
FRASER, C. G. *see* LIPWORTH, B. J.
FRCKA, G. & LADER, M. Psychotropic effects of repeated doses of enalapril, propranolol and atenolol in normal subjects, 67
FREDERICKSON, D. E. *see* WEBER, R. R.
FREESTONE, S., MACDONALD, T. M., JEFFREY, R. F. & LEE, M. R. The renal effects of atrial natriuretic peptide in man are not attenuated by D-sulpiride, 90P
FREESTONE, S. *see* MACDONALD, T. M.
FREESTONE, S. *see* MCAUSLANE, J. A. N.
FULLER, R. W. *see* BLACK, P. N.
FULLER, R. W., BLACK, P. N. & DOLLERY, C. T. Effect of oral LY 171883 on inhaled and intradermal antigen and LTD4 in atopic subjects, 626P
FULTON, J. D. *see* BARR, S. M.
FURNESS, *see* FEE, J. P. H.

GALITZKY, J., TAOUIS, M., RIVIÈRE, D., BERLAN, M., GARRIGUES, M. & LAFONTAN, M. α_2-adrenoceptor interaction with fat cell α_2-adrenoceptors, short term lipid mobilizing effects of oral yohimbine in man, 649P
GARRIGUES, M. *see* GALITZKY, J.
GEMEINHARDT, A. *see* HANDEL, J.
GENTILE, M. G. *see* BONATI, M.
GEOFFROY, J. *see* FERRY, N.
GEORGE, C. F. *see* CHALLENOR, V. F.
GEORGE, C. F. *see* RENWICK, A. G.
GEORGE, C. F. *see* ROBERTSON, D. R. C.
GHALY, R. G. *see* DUNDEE, J. W.
GIBSON, G. J. *see* GILMARTIN, J. J.
GILL, T. S., HOPKINS, K. J. & ROWLAND, M. Stereospecific assay of nicoumalone: application to pharmacokinetic studies in man, 591
GILL, T. S., DAVIES, B. E., ALLEN, G. D. & GREB, W. H. Stereospecific pharmacokinetics of cromakalim enantiomers in healthy male subjects, 669P
GILLHAM, R. A., WILLIAMS, N., WEIDMAN, K., BUTLER, E., LARKIN, J. G. & BRODIE, M. J. Concentration-effect relationships with carbamazepine and its epoxide in epileptic patients, 676P
GILLIAM, M. *see* CHIJIOKE, C. P.
GILMARTIN, J. J., CORRIS, P. A., STONE, T. N., VEALE, D. & GIBSON, G. J. Effects of diazepam and chlormethiazole on ventilatory control in normal subjects, 766
GLOCKE, M. *see* WOODWARD, S. A.
GLOVER, D. R. *see* JOHNSTON, D.
GLOVER, D. R. *see* KELLY, J. G.
GLOVER, D. R. *see* VANDENBURG, M. J.
GOADBY, P. *see* STENTON, S. C.
GOETHALS, H. *see* WALTER, M.
GOLDBERG, L. I. *see* WEBER, R. R.
GOMEZ, H. J. *see* CIRILLO, V. J.
GOTZ, V. P. *see* PARISH, R. C.
GOUGH, K. J. *see* MACDONALD, F. C.
GOUGH, K. J. *see* MACLEAN, D.
GRAHAM, R. B. *see* WALDEN, R. J.
GRAHAME-SMITH, D. G. *see* WOOD, A. J.
GRAZIANO, P. J. *see* SCAVONE, J. M.
GREAVES, M. W. *see* BARR, R. M.
GREB, W. H. *see* DAVIES, B. E.
GREB, W. H. *see* GILL, T. S.
GREENBLATT, D. J. *see* SCAVONE, J. M.
GRIMMER, S. F. M. *see* BACK, D. J.
GROSS, A. S., BAIRD-LAMBERT, J. A. & BROWN, K. F. Disposition of ritodrine in pregnant and non-pregnant women, 155P
GROVES, N. D. *see* MOUSDALE, S.

GUPTA, S. K., BAKRAN, A., JOHNSON, R. W. G. & ROWLAND, M. Erythromycin enhances the absorption of cyclosporin, 401

HAGENA, C. *see* NEUGEBAUER, G.
HAIGH, J. R. M. *see* PULLAR, T.
HAIGH, J. R. M., RHODES, L., DAVIES, J. A., ROBERTS, B. E. & FEELY, M. Use of low-dose phenobarbitone to assess the compliance of patients apparently insensitive to warfarin, 145P
HALABI, A. *see* KIRCH, W.
HALLAM, R. *see* WOODWARD, S. A.
HAMILTON, C. A. *see* BARR, S. M.
HAMILTON, T. C. *see* BAIRD, A.
HAMPSON, J. P. *see* CHRISTIE, G.
HANDEL, J., ZIEGLER, G., GEMEINHARDT, A., STUBER, H., FISCHER, C. & KLOTZ, U. Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady state, 243
HANSEN, P. B. *see* CLAUSEN, T. G.
HARLOW, B. *see* D'HEYGERE, F.
HARMATZ, J. S. *see* SCAVONE, J. M.
HARRON, D. W., DEERING, A. H., SCOTT, M., MCMAHON, M. & SHANKS, R. G. The combination of alinidine and other anti-anginal drugs on heart rate and blood pressure in amn, 154P
HARRON, D. W. G. *see* COPELAND, S.
HARRON, D. W. G. *see* DEERING, A. H.
HARRON, D. W. G. *see* KONDOWE, G. B.
HARRY, J. D. *see* ROBB, O. J.
HARRY, J. D., MILLSON, D. S. & MORTON, P. B. Use of Doppler echocardiography to determine the effects of intravenous dobutamine on cardiac function in human volunteers, 654P
HARTVIG, P. *see* PERSSON, M. P.
HAWKEY, C. J. *see* PRICHARD, P. J.
HAWKINS, C. M. A., FLETCHER, A. E., BULPITT, C. J. & PIKE, L. A. The effects of verapamil and propranolol on quality of life in hypertension, 98P
HAY, A. *see* PULLAR, T.
HAY, C. R. *see* CHOONARA, I. A.
HAYES, T. M. *see* OWENS, D. R.
HAYNES, B. P. *see* CHOONARA, I. A.
HEAGERTY, A. M. *see* WALLEY, T. J.
HEIKKILA, J. *see* PARTANEN, J.
HENDRICK, D. J. *see* STENTON, S. C.
HENRY, J. A., HLA, K. K., VOLANS, G., LATHAM, A. N. & BHAMRA, R. Influence of time of dosing on the pharmacokinetics and pharmacodynamics of sustained release verapamil, 97P
HERMANS, J. *see* OVERBOSCH, D.
HERRICK, A. L., WALLER, P. C., BERKIN, K. E., PRINGLE, S. D., ROBERTSON, M. P., CALLANDER, J. S., FINDLAY, J. G., MURRAY, G. D., REID, J. L., LORIMER, A. R., WEIR, R. J., ROBERTSON, J. I. S., BALL, S. G. & MCINNES, G. T. Enalapril and atenolol in mild to moderate hypertension, 633P
HILLBOM, M. *see* JONES, A. W.
HILLIER, K., DORRELL, L., JEWELL, R. & SMITH, C. L. Human colon mucosa. Effect of marine oils on lipid fatty acid composition and eicosanoid synthesis in inflammatory bowel disease, 129P
HILLIS, W. S. *see* THOMPSON, A. H.
HIRVISALO, E. L. *see* NEUVONEN, P. J.
HLA, K. K. *see* HENRY, J. A.
HOITSMA, A. J. *see* WETZELS, J. F. M.
HOLDING, J. D., LINDUP, W. E., BOWDLER, D. A., CAMPBELL, J., SIODLAK, M. Z. & STELL, P. M. Platinum concentration in tumours of the head and neck after intravenous cisplatin infusion, 137P
HOLGATE, S. T. *see* BEASLEY, R.
HOLGATE, S. T. *see* MISZKIEL, K. A.
HOLGATE, S. T. *see* RAFFERTY, P.
HOLGATE, S. T. *see* RICHARDS, R.
HOLLAND, R. L., TAN, P., PECK, A. W. & TELEKES, A. Dipipanone and indomethacin. Effects on electrically induced pain in volunteers, 118P
HOLMES, I. *see* ARNOUT, J.
HOLT, D. W. *see* JOHNSTON, A.
HONORÉ HANSEN, S. *see* BONDESEN, S.
HOPKINS, K. J. *see* GILL, T. S.
HORAI, Y., ZHOU, H-H., ZHANG, L. & ISHIZAKI, T. *N*-Acetylation phenotyping with dapsone in a mainland Chinese population, 81
HORAI, Y. & ISHIZAKI, T. *N*-Acetylation polymorphism of dapsone in a Japanese population, 487
HORN, C. R., STIRLING, F., COCHRANE, G. M. & ESSEX, E. Is posture clinically important when monitoring theophylline therapy?, 778
HOTCHKISS, S. A. & CALDWELL, J. Influence of sustained-release formulation upon the kinetics of metabolism of aminophylline, 645P
HOWDEN, C. W. & REID, J. L. The effect of antacid and metoclopramide on omeprazole absorption and disposition, 779
HOWE, J. P. *see* MILLIGAN, K. R.
HUMPHRIES, S. J. *see* BENNETT, P. N.
HUNTER, K. R., ANGLE, S. G., ROSEMAN, P. P. & SOPER, C. L. H. A successful multiple injection regimen using biosynthetic insulin, 663P
HUNTER, R. Steady-state pharmacokinetics of lithium carbonate in healthy subjects, 375
HUTCHINGS, A. D., MONIE, R. D., SPRAGG, B. P. & ROUTLEDGE, P. A. Saliva and plasma concentrations of isoniazid and acetylisoniazid in man, 585
HUTTON, I. *see* TWEDDEL, A. C.
HUYSMANS, F.Th.M. *see* WETZELS, J. F. M.
HVIDBERG, E. F. *see* BONDESEN, S.

IDLE, J. R. *see* AYESH, R.
IDLE, J. R. *see* OATES, N. S.
INABA, T., JORGE, L. F. & ARIAS, T. D. Mephenytoin hydroxylation in the Cuna Amerindians of Panama, 75
IRVINE, N. *see* LEWIS, R.
ISAACS, J. L., *see* BARR, R. M.
ISHIZAKI, T. *see* HORAI, Y.
IWATSUKI, S. *see* MEHTA, M. U.

JACKSON, B., CUBELA, R. B., CONWAY, E. I. & JOHNSTON, C. I. Lisinopril pharmacokinetics in chronic renal failure, 719
JACKSON, L. *see* RAFFERTY, P.
JACKSON, S. H. D. *see* DEBBAS, N. M. G.
JACKSON, S. H. D., JOHNSTON, A. & WOOLLARD, R. C. Circadian variation in theophylline absorption

during chronic dosing with a slow release preparation, 95P

JACKSON, S. H. D., JOHNSTON, A. & SHAH, K. Caffeine reduces the clearance of theophylline in the presence of a normal dietary methyl xanthine intake, 134P

JACKSON, S. H. D. & JOHNSTON, A. Intraindividual variation in theophylline pharmacokinetics—the application of repeatability analysis, 642P

JAMALUDIN, A., MOHAMAD, M., NAVARATNAM, V., SELLIAH, TAN, S. C., WERNSDORFER, W. H. & YUEN, K. H. Relative bioavailability of the hydrochloride, sulphate and ethyl carbonate salts of quinine, 261

JAMES, I. *see* D'HEYGERE, F.

JANSSON, C. *see* NYBERG, G.

JAYASINGHE, K. S. A. *see* FORSYTH, D. R.

JEFFREY, R. F. *see* FREESTONE, S.

JEFFREY, R. F. *see* MACDONALD, T. M.

JEFFREY, R. F., MACDONALD, T. M. & LEE, M. R. Lithium attenuates the renal response to γ-L-glutamyl-l-dopa in man, 91P

JEFFREY, R. F., MACDONALD, T. M., MARWICK, K. & LEE, M. R. The effect of carbidopa and indomethacin on the renal response to γ-L-glutamyl-L-dopa in normal man, 195

JEFFREY, R. F., MACDONALD, T. M., BROWN, J., RAE, P. W. H. & LEE, M. R. The effect of lithium on the renal response to the dopamine prodrug gludopa in normal man, 725

JEWELL, R. *see* HILLIER, K.

JOHN, S. *see* MÖNIG, H.

JOHNSON, R. W. G. *see* GUPTA, S. K.

JOHNSTON, A. *see* CHIJIOKE, P. C.

JOHNSTON, A. *see* DEBBAS, N. M. G.

JOHNSTON, *see* JACKSON, S. H. D.

JOHNSTON, A. *see* LEWIS, R.

JOHNSTON, A., MARSDEN, J. T. & HOLT, D. W. The influence of haematocrit on blood cyclosporin measurements *in vivo*, 132P

JOHNSTON, A., MARSDEN, J. T. & HOLT, D. W. The influence of haematocrit on blood cyclosporin measurements *in vivo*, 509

JOHNSTON, C. I. *see* JACKSON, B.

JOHNSTON, D., RICHARDSON, P. J., MEANY, B., LONG, C. & GLOVER, D. R. Lisinopril in the management of severe hypertension: a six month study, 655P

JOHNSTON, G. D. *see* KONDOWE, G. B.

JOHNSTON, G. D. *see* MCVEIGH, G. E.

JOHNSTON, G. D. *see* PASSMORE, A. P.

JONES, A. K. P., LUTHRA, S. K., MAZIERE, B., PIKE, V. W., LOC'H, C. & STULZAFT, D. *In vivo* opioid receptor binding in rats and man using [^{11}C]-diprenorophine, 119P

JONES, A. W., NEIMAN, J. & HILLBOM, M. Concentration-time profiles of ethanol and acetaldehyde in human volunteers treated with the alcohol-sensitizing drug, calcium carbimide, 213

JONES, D. *see* MERCER, A.

JONSSON, U. E. *see* NYBERG, G.

JORGE, L. F. *see* INABA, T.

JUBBER, A. *see* BRANDMAN, S.

JUPE, D. M. L., PETERSON, G. M., COLEMAN, R. L. & MCCLEAN, S. Warfarin dosage requirements: prospective clinical trial of a method for prediction from the response to a single dose, 607

KALIMAN, J. *see* SINZINGER, H.

KARADIA, S. R. *see* RUST, N. D.

KEELING, P. W. N. *see* MACMUTHANA, P.

KELLY, C. A. *see* STENTON, S. C.

KELLY, J. G. *see* VANDENBURG, M. J.

KELLY, J. G., DOYLE, G. D., CARMODY, M., GLOVER, D. R. & COOPER, W. D. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis, 634P

KELMAN, A. W. *see* THOMPSON, A. H.

KENDALL, M. J. *see* CHELLINGSWORTH, M. C.

KILBY, P., MALLETT, D. N., FACCHINI, V. & SMITH, S. E. A comparison of the bioavailability of chloroquine form nivaquine syrup and a nivaquine tasteless suspension, 670P

KIMBER, S. *see* WOODWARD, S. A.

KINGSTON, W. P. *see* STENTON, S. C.

KIRCH, W., HALABI, A. & OHNHAUS, E. E. Negative inotropic effects of famotidine, 635P

KITCHINGMAN, G. *see* PRICHARD, P. J.

KITTERINGHAM, N. R. *see* LAMBERT, C.

KLOTZ, U. *see* HANDEL, J.

KNOX, A. J., TATTERSFIELD, A. E. & BRITTON, J. R. The effect of inhaled ouabain on bronchial reactivity to histamine in man, 758

KOBAYASHI, S. *see* ZHI-GUANG, T.

KOBAYASHI, S., SPEIRS, C. J., WATSON, D., MURRAY, S., SESARDIC, D. & BOOBIS, A. R. Time course of inhibition by quinidine of debrisoquine 4-hydroxylase activity in man, 673P

KOBZA BLACK, A. *see* BARR, R. M.

KOENE, F. M. M. *see* VAN BAAK, M. A.

KOENE, R. A. P. *see* WETZELS, J. F. M.

KÖETER, G. H. *see* FEITSMA, K. G.

KONDOWE, G. B., DEERING, A. H., RIDDELL, J. G., JOHNSTON, G. D. & HARRON, D. W. G. The effect of acute and chronic captopril therapy on baroreflex function in man, 315

KONGOLA, G. *see* RIMMER, E.

KORO, O. *see* BARR, R. M.

KOVISTÖ, K. *see* NEUVONEN, P. J.

KRIEK, E. *see* CHANG, P. C.

KRISTIANSON, K. *see* CIRILLO, V. J.

KÜPFER, A. *see* EICHELBAUM, M.

LADER, M. *see* FRCKA, G.

LAFONTAN, M. *see* GALITZKY, J.

LAMBERT, C., MAGGS, J. L., PARK, B. K. & KITTERINGHAM, N. R. Formation of chemically reactive drug metabolites by activated human polymorphonuclear leucocytes, 143P

LANG, C. M. *see* MCMURRAY, J.

LANT, A. F. *see* DIXEY, J. J.

LARKIN, J. G. *see* GILLHAM, R. A.

LARKIN, J. G., MCGUIRE, G. M., PERCY-ROBB, I. & BRODIE, M. J. Anticonvulsant monitoring at the epilepsy clinic: a prospective study, 627P

LARSEN, F. *see* CLAUSEN, T. G.

LATHAM, A. N. *see* BOCHSLER, J. A.

LATHAM, A. N. *see* HENRY, J. A.

LAWSON, A. A. H. *see* MCMURRAY, J.
LAWSON, D. H. *see* CHALMERS, D.
LEE, M. R. *see* FREESTONE, S.
LEE, M. R. *see* JEFFREY, R. F.
LEE, M. R. *see* MACDONALD, T. M.
LEES, K. R. *see* BARR, S. M.
LEES, K. R. & REID, J. L. Lisinopril and nifedipine: No acute interaction in normotensives, 307
LENNARD, M. S. *see* MCCOURTY, J. C.
LENNARD, M. S. *see* OTTON, S. V.
LENNARD, M. S., MCGOURTY, J. C. & SILAS, J. H. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin, 276
LENNOX, I. M. *see* MACPHEE, G. J. A.
LEWIS, I. J. *see* CHOONARA, I. A.
LEWIS, R. *see* CURRIE, D.
LEWIS, R., IRVINE, N. & MCDEVITT, D. G. Effects of digoxin, verapamil and diltiazem upon heart rate, exercise tolerance and cardiac output in atrial fibrillation, 101P
LEWIS, R., MACLEAN, D., MCDEVITT, D. & JOHNSTON, A. Bisoprolol in the treatment of mild hypertension, 152P
LEWIS, R. V. & MCDEVITT, D. G. Factors affecting the clinical response to treatment with digoxin and two calcium antagonists in patients with atrial fibrillation, 603
LIEBENS, I. *see* WALTER, M.
LIN, E. S. *see* AITKENHEAD, A. R.
LINDUP, W. E. *see* HOLDING, J. D.
LING, T. *see* D'HEYGERE, F.
LINGE, K. *see* ROBERTS, D. H.
LIPWORTH, B. J., CLARK, R. A., DHILLON, D. P. & MCDEVITT, D. G. β-adrenoceptor responses to high doses of inhaled salbutamol aerosol in asthma, 625P
LIPWORTH, B. J., CLARK, R. A., DHILLON, D. P., FRASER, C. G. & MCDEVITT, D. G. Metabolic effects of cumulative doses of salbutamol from a metered-dose inhaler in bronchial asthma, 667P
LIS, Y. *see* PRENTIS, R. A.
LIU, J. B. *see* WALDEN, R. J.
LØBERG, R. *see* MATHESON, I.
LOC'H, C. *see* JONES, A. K. P.
LOCKE-HAYDON, J., SCOTT, S. C. & VILLAR, B. L. B. Ibopamine (SK & F 100168) does not potentiate the cardiovascular response to tyramine in healthy subjects, 154P
LONG, C. *see* JOHNSTON, D.
LONG, C. *see* VANDENBURG, M. J.
LOOAREESUWAN, S. *see* EDWARDS, G.
LORIMER, A. R. *see* HERRICK, A. L.
LOUDON, J. M., MCCLEILAND, G. R. & PILGRIM, A. J. Denbufylline and ethanol. Effects on psychomotor performance, 123P
LOWE, J. R. *see* PULLAR, T.
LOYSEN, E. *see* BROWN, M. J.
LUSCOMBE, D. K. *see* SHAYEGAN-SALEK, M. S.
LUTHRA, S. K. *see* JONES, A. K. P.
LUZIO, S. *see* OWENS, D. R.
LYNN, K. L. *see* BAILEY, R. R.

MACDONALD, F. C. *see* MACLEAN, D.
MACDONALD, F. C., GOUGH, K. J., NICOLL, R. A. G. & DOW, R. J. Psychomotor effects of ketorolac, a new analgesic, in comparison with buprenorphine and diclofenac, 628P
MACDONALD, T. M. *see* FREESTONE, S.
MACDONALD, T. M. *see* JEFFREY, R. F.
MACDONALD, T. M., JEFFREY, R. F., FREESTONE, S. & LEE, M. R. (+)-sulpiride antagonises the renal effects of γ-L-glutamyl-L-dopa in man, 203
MACKIE, A. M. *see* MOUSDALE, S.
MACKIE, R. *see* MCLELLAN, A. R.
MACKLIN, B. *see* RENWICK, A. G.
MACLEAN, D. *see* LEWIS, R.
MACLEAN, D. *see* MCMURRAY, J.
MACLEAN, D., MITCHELL, E. T., COULSON, R. R., FITZSIMONS, T. J. & MCDEVITT, D. G. Atenolol-nifedipine combinations compared with atenolol alone in hypertension: efficacy and tolerability, 425
MACLEAN, D., MITCHELL, E. T., MACDONALD, F. C., GOUGH, K. J., DOW, R. J. & MCDEVITT, D. G. Efficacy and acceptability of twice daily nicardipine and propranolol in mild to moderate hypertension, 636P
MACMUTHANA, P., FOLEY, B., O'REILLY, T., BARRY, M., KEELING, P. W. N. & FEELY, J. Splanchnic and systemic haemodynamic effects of vasopressin and nifedipine in cirrhosis and portal hypertension, 621P
MACONOCHIE, J. G., FORSTER, J. K., FOWLER, P. & THOMAS, M. An initial comparison of salmeterol and salbutamol against histamine-induced bronchoconstriction in healthy subjects, 115P
MACPHEE, G. J. A., MITCHELL, J. R., WISEMAN, L., MCLELLAN, A. R., PARK, B. K., MCINNES, G. T. & BRODIE, M. J. Effect of sodium vaslproate on carbamazepine disposition and psychomotor profile in man, 59
MACPHEE, G. J. A., DUTTON, M., LENNOX, I. M. & WILLIAMS, B. O. Effect of nifedipine retard 10 mg twice daily in elderly hypertensive patients, 661P
MADDEN, S. *see* BACK, D. J.
MAGGS, J. L. *see* LAMBERT, C.
MAGGS, J. L. & PARK, B. K. Cytotoxicity of the quinoneimine of amodiaquine, 143P
MAILE, P. A. *see* RAPEPORT, W. C.
MALIA, R. G. *see* CHOONARA, I. A.
MALLETT, D. N. *see* KILBY, P.
MANARA, A. R., SHELLY, M. P., QUINN, K. & PARK, G. R. The effect of metoclopramide on the absorption of oral controlled release morphine, 518
MANN, R. D. *see* BACK, D. J.
MANNERING, D. *see* VANDENBURG, M. J.
MARKS, V. *see* MOULD, G. P.
MARLEY, J. Post marketing surveillance of captopril, 781
MARRIOTT, B. A. *see* BENNETT, P. N.
MARSDEN, C. A. *see* SWIRE, F. M. M.
MARSDEN, J. T. *see* JOHNSTON, A.
MARSHALL, R. *see* MERCER, A.
MARTIN, C. A. *see* BACK, D. J.
MARTIN, W. *see* TWEDDEL, A. C.
MARWICK, K. *see* JEFFREY, R. F.
MATHESON, I., SAMSETH, M., LØBERG, R., FÆGRI, A. & PRENTICE, A. Milk transfer of phenoxymethyl-

penicillin during puerperal mastitis, 33
MATTIE, H. *see* BINS, J. W.
MATTIE, H. *see* OVERBOSCH, D.
MATTILA, M. E. *see* MATTILA, M. J.
MATTILA, M. J., MATTILA, M. E., ARANKO, K. & SEPPÄLÄ, T. Pharmacodynamic and pharmacokinetic studies on the actions of two benzodiazepines and flupenthixol on human performance, 110P
MAZIERE, B. *see* JONES, A. K. P.
MCAUSLANE, J. A. N., FREESTONE, S. COWIE, J. & PRESCOTT, L. F. Tenoxicam. Effect on renal function in normal man, 93P
MCBRYAN, D. D. *see* BARR, S. M.
MCBURNEY, A. *see* AYESH, R.
MCCAFFREY, P. M., RIDDELL, J. G. & SHANKS, R. G. An assessment of the selectivity of some β_2-adrenoceptor agonists in man, 650P
MCCLEAN, E. *see* MILLIGAN, K. R.
MCCLEAN, S. *see* JUPE, D. M. L.
MCCLELLAND, G. R. *see* LOUDON, J. M.
MCCOLLUM, J. S. C. *see* FEE, J. P. H.
MCCOURTY, J. C., SILAS, J. H., TUCKER, G. T. & LENNARD, M. S. The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris, 349
MCCOY, C. E. *see* WEBER, R. R.
MCCREAR, C. *see* O'BOYLE, C. A.
MCDEVITT, D. *see* LEWIS, R.
MCDEVITT, D. G. *see* CURRIE, D.
MCDEVITT, D. G. *see* LEWIS, R.
MCDEVITT, D. G. *see* LIPWORTH, B. J.
MCDEVITT, D. G. *see* MACLEAN, D.
MCDEVITT, D. G. *see* MCMURRAY, J.
MCDEVITT, D. G. *see* NICHOLSON, A. N.
MCDIARMAID-GORDON, A. *see* CHRISTIE, G.
MCEWEN, J. *see* MCKENZIE, A. A.
MCGHIE, A. I. *see* TWEDDEL, A. C.
MCGOURTY, J. C. *see* LENNARD, M. S.
MCGUIRE, G. M. *see* LARKIN, J. G.
MCINNES, G. T. *see* HERRICK, A. L.
MCINNES, G. T. *see* MACPHEE, G. J. A.
MCINNES, G. T. *see* MCLELLAN, A. R.
MCINNES, G. T. & BRODIE, M. J. Concentration-effect relationships for oxprenolol in patients with essential hypertension, 539
MCINTYRE, N. *see* D'HEYGERE, F.
MCKAIGUE, J. J. *see* WHITEHEAD, E. M.
MCKENZIE, A. A., MCEWEN, J. & MORELAND, T. A. An h.p.l.c. -fluorescence method for the assay of plasma sulpiride after low dose administration, 668P
MCLELLAN, A. R. *see* MACPHEE, G. J. A.
MCLELLAN, A. R., RENTOUL, J., MACKIE, R. & MCINNES, G. T. Spironolactone lacks efficacy in female hirsutism, 128P
MCLOUGHLIN, G. A. *see* ROBERTS, D. H.
MCMAHON, M. *see* HARRON, D. W.
MCMURRAY, J., SEIDELIN, P. H. & STRUTHERS, A. D. Intrarenal sites of action of atrial natriuretic factor in man, 630P
MCMURRAY, J., LANG, C. M., STRUTHERS, A. D., MACLEAN, D. & MCDEVITT. Current use of ACE inhibitors in the treatment of chronic heart failure, 646P
MCMURRAY, J., SEIDELIN, P. H. & STRUTHERS, A. D. Low dose angiotensin II enhances proximal tubular sodium reabsorption in man, 90P
MCMURRAY, J., NORTHRIDGE, D. B. & LAWSON, A. A. H. Trends in analgesic self-poisoning, 120P
MCMURRAY, T. J. *see* FLYNN, R. J.
MCVEIGH, G. E., DULIE, E. & JOHNSTON, G. D. Effect of cyclopenthiazide on glucose tolerance and plasma lipoproteins in mild essential hypertension. 104P
MEADE, T. W., PARK, B. K., STIRLING, Y., WILKES, H. & WINN, M. J. Pharmacological response to low-dose warfarin in patients at high risk of ischaemic heart disease, 146P
MEANY, B. *see* JOHNSTON, D.
MEESE, C. O. *see* EICHELBAUM, M.
MEHTA, J. L. *see* PARISH, R. C.
MEHTA, M. U., VENKATARAMANAN, R., BURCKART, G. J., PTACHCINSKI, R. J., DELAMOS, B., STACHAK, S., VAN THIEL, D. H., IWATSUKI, S. & STARZL, T. E. Effect of bile on cyclosporin absorption in liver transplant patients, 579
MEKKI, Q. A. *see* ANKIER, S. I.
MEKKI, Q. A. *see* WARRINGTON, S. J.
MELLOWS, G. *see* DAVIES, B. E.
MELVIN, W. T. *see* MURRAY, G. I.
MENARD, J. *see* BELLETT, M.
MERCER, A., ALLEN, E., JONES, D., MARSHALL, R., WROE, S. & RICHENS, A. The effects of minaprine and chlorpromazine, alone and in combination, on human psychomotor performance and mood, 680P
MEREDITH, P. A. *see* DONNELLY, R.
MEYER, E. C., SOMMERS, DE.K., SCHOEMAN, H. S. & AVENANT, J. C. The effect of atropine on heart-rate: a comparison between two ethnic groups, 776
MICHAEL, M. F. *see* THOMAS, M.
MILLAR, A. *see* BUSH, A.
MILLIGAN, J. G. L. *see* COPELAND, S.
MILLIGAN, K. R., HOWE, J. P., MCCLEAN, E. & DUNDEE, J. W. The effect of perioperative alfentanil and fentanyl on postoperative gastric emptying, 108P
MILLSON, D. S. *see* HARRY, J. D.
MINERS, J. O. *see* ROBSON, R. A.
MISTRY, K. *see* BARR, R. M.
MISZKIEL, K. A., BEASLEY, R., RAFFERTY, P. & HOLGATE, S. T. The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chloride in asthma, 157
MITCHELL, E. T. *see* MACLEAN, D.
MITCHELL, J. R. *see* MACPHEE, G. J. A.
MITCHELL, S. C. *see* AYESH, R.
MIYAMOTO, Y. *see* ARNOUT, J.
MOHAMAD, M. *see* JAMALUDIN, A.
MÖLLENDORFF, E. V. *see* NEUGEBAUER, G.
MONIE, R. D. *see* HUTCHINGS, A. D.
MÖNIG, H., WILHELMY, J., JOHN, S. & OHNHAUS, E. E. Biliary excretion of antipyrine and its metabolities after cholecystectomy, 279
MOODY, S. G. *see* POSNER, J.
MOORE, J. *see* FLYNN, R. J.

MORELAND, T. A. *see* MCKENZIE, A. A.
MORICE, A. H. *see* BROWN, M. J.
MORRISON, R. A. *see* SINGHVI, S. M.
MORTON, P. B. *see* HARRY, J. D.
MOULD, G. P. & MARKS, V. An audit of digoxin serum concentration monitoring, 138P
MOUSDALE, S., CLYBURN, P. A., MACKIE, A. M., GROVES, N. D. & ROSEN, M. Comparison of the effects of dopamine, dobutamine, and dopexamine upon renal blood flow: a study in normal healthy volunteers, 555
MURPHY, M. B. *see* WEBER, R. R.
MURRAY, B. *see* ZHI-GUANG, T.
MURRAY, G. D. *see* HERRICK, A. L.
MURRAY, G. I., BARNES, T. S., SEWELL, H. F., EWEN, S. W. B., MELVIN, W. T. & BURKE, M. D. The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450, 465
MURRAY, S. *see* BENNETT, P. N.
MURRAY, S. *see* KOBAYASHI, S.
MURRAY, S. *see* ZHI-GUANG, T.
MYALL, O. *see* PULLAR, T.

NAVARATNAM, V. *see* JAMALUDIN, A.
NEIMAN, J. *see* JONES, A. W.
NEUGEBAUER, G., AKPAN, W., HAGENA, C., MÖLLENDORFF, E. V. & SCHRÖTER, E. Haemodynamic effects of the new position inotrope adibendan after oral administration in healthy subjects, 655P
NEUVONEN, P. J., KOVISTÖ, K. & HIRVISALO, E. L. Effects of resins and activated charcoal on the absorption of digoxin, carbamazepdine and frusemide, 229
NEWBY, S. *see* CHRISTIE, G.
NICHOLLS, D. P. *see* ELBORN, J. S.
NICHOLSON, A. N. *see* CURRIE, D.
NICHOLSON, A. N., WRIGHT, N. A., ZETLEIN, M. B., CURRIE, D. & MCDEVITT, D. G. Effects of the β-adrenoceptor antagonists propanolol and atenolol on the electroencephalogram and on body sway, 125P
NICOLL, R. A. G. *see* MACDONALD, F. C.
NIEMINEN, M. S. *see* PARTANEN, J.
NINCI, R. *see* SGARAGLI, G. P.
NIXON, D. P. *see* ROBERTS, D. H.
NOORMOHAMED, F. H. *see* DIXEY, J. J.
NORTHCOTE, R. J. & BALLANTYNE, D. The influence of β-adrenoceptor blockers with and without intrinsic sympathomimetic activity on heart rate, arrhythmias and ST-T segments, using ambulatory electrocardiography, 179
NORTHRIDGE, D. B. *see* MCMURRAY, J.
NOSSENT, G. D. *see* FEITSMA, K. G.
NOTARIANNI, L. J. *see* BENNETT, P. N.
NOTARIANNI, L. J. *see* FORDYCE, K. S.
NYBERG, G., JANSSON, C., JONSSON, U. E. & SINDEBY CULLBERG, M. Pharmacokinetic properties of a new extended release quinidine product, 97P
NYBERG, R. *see* CIRILLO, V. J.

OATES, N. S., FEHER, M. D., PERRY, H. E., SCHMID, B. J., SEVER, P. S. & IDLE, J. R. Influence of quinidine on nifedipine plasma pharmacokinetics, 675P
O'BOYLE, C. A., BARRY, H., FOX, E., MCCREAR, C. & BEWLEY, A. Benzodiazepine-induced amnesia in different sensory modalities following oral surgery, 677P
O'BYRNE, S. *see* O'CONNOR, P.
O'CONNOR, P., COLLINS, W., CULLEN, M., CRANNY, A., O'BYRNE, S. & FEELY, J. Calcium antagonists and pituitary function: elevation of prolactin by verapamil, 659P
OHNHAUS, E. E. *see* MÖNIG, H.
OHNHAUS, E. E. *see* KIRCH, W.
O'REILLY, T. *see* MACMUTHANA, P.
ORME, L'E. *see* BALL, S.
ORME, M. L. E. *see* BACK, D. J.
OSBORNE, J. P. *see* BENNETT, P. N.
O'SULLIVAN, D. P. D. *see* AL-SEREITI, M. R.
OTERI, G. *see* PISANI, F.
OTTON, S. V., LENNARD, M. S., TUCKER, G. T. & WOODS, H. F. Effect of quinidine and quinine on metoprolol oxidation in human liver microsomes, 644P
OVERBOSCH, D., VAN GULPEN, C., HERMANS, J. & MATTIE, H. The effect of probenecid on the renal tubular excretion of benzylpenicillin, 51
OWENS, D. R., VORA, J. P., BIRTWELL, J., LUZIO, S. & HAYES, T. M. The influence of aprotinin on regional absorption of soluble human insulin, 453

PAALZOW, L. *see* PERSSON, M. P.
PAALZOW, L. *see* SUNZEL, M.
PALMI, M. *see* SGARAGLI, G. P.
PARISH, R. C., GOTZ, V. P. & MEHTA, J. L. Cimetidine does not increase α_1-acid glycoprotein serum concentrations, 514
PARK, B. K. *see* CHOONARA, I. A.
PARK, B. K. *see* CHRISTIE, G.
PARK, B. K. *see* LAMBERT, C.
PARK, B. K. *see* MACPHEE, G. J. A.
PARK, B. K. *see* MAGGS, J. L.
PARK, G. R. *see* MANARA, A. R.
PARK, B. K. *see* MEADE, T. W.
PARTANEN, J., HEIKKILA, J., PELLINEN, T. & NIEMINEN, M. S. Effect of digoxin on the heart in normal subjects: influence of isometric exercise and autonomic blockade: A noninvasive study, 331
PASSMORE, A. P. & JOHNSTON, G. D. A comparison of the renal effects of ibuprofen and indomethacin in subjects with moderate salt restriction, 92P
PASSMORE, A. P., WHITEHEAD, E. M. & JOHNSTON, G. D. A comparison of the acute effects of low and high doses of frusemide and bumetanide on renal and peripheral haemodynamics, 621P
PATEL, K. R. & PEERS, E. M. Felodopine modifies exercise-induced asthma, 115P
PATTERSON, C. C. *see* DUNDEE, J. W.
PEARSON, R. M. *see* CHIJIOKE, P. C.
PEARSON, R. M. *see* RAOOF, N. T.
PECK, A. W. *see* HOLLAND, R. L.
PECK. A. W. *see* POSNER, J.
PEDDIE, B. A. *see* BAILEY, R. R.

PEDERSEN, S. *see* STEFFENSEN, G.
PEDERSEN, V. *see* BONDESEN, S.
PEERS, E. M. *see* PATEL, K. R.
PELLINEN, T. *see* PARTANEN, J.
PERCY, H. E. *see* OATES, N. S.
PERRY-ROBB, I. *see* LARKIN, J. G.
PERSSON, M. P., HARTVIG, P., WIKLUND, L. & PAALZOW, L. Pulmonary disposition of pethidine in postoperative patients, 235
PERUCCA, E. *see* PISANI, F.
PETERSON, G. M. *see* JUPE, D. M. L.
PETRIE, J. C. *see* ROBB, O. J.
PETRIE, J. C. *see* SCOTT, A. K.
PETRIE, J. C. *see* WEBSTER, J.
PEZZETTA, A. *see* SCARPIGNATO, C.
PHILLIPS, G. D. *see* RICHARDS, R.
PHILLIPS, R. E. *see* EDWARDS, G.
PIKE, L. A. *see* HAWKINS, C. M. A.
PIKE, V. W. *see* JONES, A. K. P.
PILGRIM, A. J. *see* LOUDON, J. M.
PIPER, P. J. *see* EVANS, J. M.
PISANI, F., FAZIO, A., OTERI, G., SPINA, E., PERUCCA, E. & BERTILSSON, L. Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide, 611
POHL, J. E. F. *see* WALLEY, T. J.
POITEVIN, B., DAVENAS, E. & BENVENISTE, J. *In vitro* immunological degranulation of human basophils is modulated by Lung histamine and Apis mellifica, 439
PONIATOWSKA, T. J. *see* PRICHARD, P. J.
POSNER, J., MOODY, S. G., PECK, A. W., RUTTER, G. & TELEKES, A. Pharmacodynamics of a novel opioid peptide BW 443C in healthy volunteers, 120P
POSTMA, D. S. *see* FEITSMA, K. G.
POZET, N. *see* FERRY, N.
PRENTICE, A. *see* MATHESON, I.
PRENTIS, R. A., LIS, Y. & WALKER, S. R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964–1985), 387
PRESCOTT, L. F. *see* MCAUSLANE, J. A. N.
PRESTON, F. E. *see* CHOONARA, I. A.
PRICHARD, P. J., PONIATOWSKA, T. J., WILLARS, J. E. & HAWKEY, C. J. Effect in man of aspirin, standard indomethacin, and sustained release preparations on gastric micro-bleeding, 131P
PRICHARD, P. J., KITCHINGMAN, G. & HAWKEY, C. J. Gastric mucosal bleeding caused by aspirin 75mg but not low dose warfarin in human subjects, 131P
PRICHARD, B. N. C. *see* WALDEN, R. J.
PRINGLE, S. D. *see* HERRICK, A. L.
PROUDLOVE, C. *see* BACK, D. J.
PTACHCINSKI, R. J. *see* MEHTA, M. U.
PUGH, S. *see* SHAYEGAN-SALEK, M. S.
PULLAR, T., BIRTWELL, A. J., WILES, P. G., HAY, A. & FEELY, M. P. A comparison of compliance with tablets prescribed to be taken once, twice or three times daily, 641P
PULLAR, T., MYALL, O., DIXON, J. S., HAIGH, J. R. M., LOWE, J. R. & BIRD, H. A. Allopurinol has no effect on steady-state concentrations of indomethacin, 672P
PULLAR, T., MYALL, O., HAIGH, J. R. M., LOWE, J. R., DIXON, J. S. & BIRD, H. A. The effect of allopurinol on the steady-state pharmacokinetics of indomethacin, 755
PULLEN, F. H. *see* RAPEPORT, W. G.

QUINN, K. *see* BAILLIE, S. P.
QUINN, K. *see* MANARA, A. R.

RAE, P. W. H. *see* JEFFREY, R. F.
RAFFERTY, P. *see* BEASLEY, R.
RAFFERTY, P. *see* MISZKIEL, K. A.
RAFFERTY, P., JACKSON, L., SMITH, R. & HOLGATE, S. T. Terfenadine in the treatment of grass pollen sensitive asthmatics during the hay fever season, 623P
RAFIOLSADAT, Z. *see* BONDESEN, S.
RAMSAY, L. E. *see* CAMERON, H. A.
RAMSEY, L. E. *see* WALLER, P. C.
RAOOF, N. T. & PEARSON, R. M. Propranolol concentration in blood, seminal plasma and saliva in man after single and multiple oral doses, 144P
RAPEPORT, W. G. *see* ARNOLD, B. D. C.
RAPEPORT, W. G. *see* COOPER, S. M.
RAPEPORT, W. G. *see* ZUSSMAN, B. D.
RAPEPORT, W. G., COOPER, S. M., MAILE, P. A. & PULLEN, F. H. The effects of BRL 24924 A novel gastric prokinetic agent, on circulating hormone concentrations in man, 127P
RASMUSSEN, S. N. *see* CLAUSEN, T. G.
RAUSCHA, F. *see* SINZINGER, H.
RAWLINS, M. D. *see* FERNER, R. E.
RAYNER, P. *see* CHOONARA, I. A.
RECKLESS, J. P. D. *see* BENNETT, P. N.
REID, C. *see* WHYTE, K. F.
REID, J. L. *see* BARR, S. M.
REID, J. L. *see* DONNELLY, R.
REID, J. L. *see* HERRICK, A. L.
REID, J. L. *see* HOWDEN, C. W.
REID, J. L. *see* LEES, K. R.
REID, J. L. *see* SUMMER, D. J.
REID, J. L. *see* WHYTE, K. F.
REID, P. G., WATT, A. H., ROUTLEDGE, P. A. & STEPHENS, M. R. Concentration-effect relationship for adenosine-induced respiratory stimulation, 116P
RENARD, M. *see* WALTER, M.
RENTOUL, J. *see* MCLELLAN, A. R.
RENWICK, A. G. *see* CHALLENOR, V. F.
RENWICK, A. G. *see* RICHARDS, R.
RENWICK, A. G. *see* ROBERTSON, D. R. C.
RENWICK, A. G., ROBERTSON, D. R. C., MACKLIN, B., CHALLENOR, V., WALLER, D. G. & GEORGE, C. F. The pharmacokinetics of oral nifedipine—a population study, 701
RHODES, L. *see* HAIGH, J. R. M.
RICHARDS, D. H. *see* BAIRD, A.
RICHARDS, R. K. *see* BAX, N. D. S.
RICHARDS, R., FOWLER, C., SIMPSON, S., RENWICK, A. G., BRITTEN, A. & HOLGATE, S. T. Inhaled histamine increases the rate of absorption of inhaled sodium cromoglycate, 665P
RICHARDS, R., PHILLIPS, G. D. & HOLGATE, S. T. The comparative inhibitory effect of nedocromil

sodium and sodium cromoglycate on adenosine induced bronchoconstriction, 666P
RICHARDSON, P. J. *see* JOHNSTON, D.
RICHENS, A. *see* RIMMER, E.
RICHENS, A. *see* MERCER, A.
RIDDELL, J. G. *see* COPELAND, S.
RIDDELL, J. G. *see* DEERING, A. H.
RIDDELL, J. G. *see* KONDOWE, G. B.
RIDDELL, J. G. *see* MCCAFFREY, P. M.
RIDDELL, J. G. *see* WHITEHEAD, E. M.
RIMMER, E., KONGOLA, G. & RICHENS, A. Inhibition of the enzyme, GABA-aminotransferase in human platelets by vigabatrine, a potential antiepileptic drug, 251
RISSANEN, *see* CIRILLO, V. J.
RIVIÈRE, D. *see* GALITZKY, J.
ROATH, O. S. *see* FRANCIS, J. L.
ROBB, O. J., WEBSTER, J., PETRIE, J. C., HARRY, J. D. & YOUNG, J. Effects of the β_2-adrenoceptor antagonist ICI 118,551 on blood pressure in hypertensive patients known to respond to β_1-adrenoceptor antagonists, 433
ROBERTS, B. E. *see* HAIGH, J. R. M.
ROBERTS, C. J. C. *see* FORSYTH, D. R.
ROBERTS, D. H., LINGE, K., NIXON, D. P., CHATLANI, P. T., MCLOUGHLIN, G. A. & BRECKENRIDGE, A. M. The effects of iloprost on calf blood flow in patients with severe peripheral arterial disease, 147P
ROBERTS, D. H., LINGE, K., NIXON, D. P., CHATLANI, P. T., MCLOUGHLIN, G. A. & BRECKENRIDGE, A. M. The effects of iloprost on calf blood flow in patients with stable intermittent claudication, 148P
ROBERTS, D. H., TSAO, Y., LINGE, K., CHATLANI, P. T., MCLOUGHLIN, G. A., & BRECKENRIDGE, A. M. Double-blind comparison of captopril or nifedipine in hypertension complicated by intermittent claudication, 631P
ROBERTSON, D. R. C., WALLER, D. G., RENWICK, A. G. & GEORGE, C. F. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine, 297
ROBERTSON, D. R. C. *see* RENWICK, A. G.
ROBERTSON, J. I. S. *see* HERRICK, A. L.
ROBERTSON, M. P. *see* HERRICK, A. L.
ROBSON, R. A., MINERS, J. O. & BIRKETT, D. J. Selective inhibitory effects of nifedipine and verapamil on oxidative metabolism: effects of theophylline, 397
ROBSON, R. A., FRAENKEL, M., BARRATT, L. J. & BIRKETT, D. J. Cyclosporin-verapamil interaction, 402
ROBSON, R. H. Post-marketing surveillance, 404
RODGERS, A., WOODHOUSE, K. W. & BATEMAN, D. N. Once nightly sustained release theophylline in elderly subjects, 523
ROSEMAN, P. P. *see* HUNTER, K. R.
ROSEN, M. *see* MOUSDALE, S.
ROSINA, R. *see* BONATI, M.
ROUTLEDGE, P. A. *see* HUTCHINGS, A. D.
ROUTLEDGE, P. A. *see* REID, P. G.
ROWLAND, M. *see* GILL, T. S.
ROWLAND, M. *see* GUPTA, S. K.
ROYCHOUDHURY, D. *see* BRANDMAN, S.
RUDD, P. T. *see* BENNETT, P. N.
RUDORF, J. *see* WOODWARD, S. A.
RUST, N. D., KARADIA, S. R., WHITTAM, L. R. & CHAPUT DE SAINTONGE, D. M. Modelling determinants of expected rewards in human volunteers, 681P
RUTTER, G. *see* POSNER, J.

SALONEN, J. *see* CIRILLO, V. J.
SALONEN, R. *see* CIRILLO, V. J.
SAMSETH, M. *see* MATHESON, I.
SASSARD, J. *see* FERRY, N.
SCADDING, G. *see* AYESH, R.
SCARPIGNATO, C., VITULO, F., ZIMBARO, G. & PEZZETTA, A. Effect of some H_2-receptor antagonists on gastric emptying of solids in humans. Are H_2-receptors involved?, 111P
SCAVONE, J. M., GREENBLATT, D. J., BLYDEN, G. T., HARMATZ, J. S. & GRAZIANO, P. J. Simplified approaches to the determination of antipyrine pharmacokinetic parameters, 695
SCHAFERS, R. F. & ELLIOTT, H. L. An evaluation of the α-adrenoceptor antagonism produced by SK & F 86466 in healthy normotensive volunteers, 648P
SCHMID, B. J. *see* OATES, N. S.
SCHOEMAN, H. S. *see* MEYER, E. C.
SCHRÖTER, E. *see* NEUGEBAUER, G.
SCOTT, A. K., WEBSTER, J., PETRIE, J. C. & BASTAIN, W. The effect of age and cardiac failure on xamoterol pharmacokinetics, 165
SCOTT, A. K., CHAUDHURY, P. R., WEBSTER, J. & PETRIE, J. C. Selective 5-HT antagonist (ICI 169,369): lack of effect on blood pressure in hypertensive patients, 651P
SCOTT, M., CASTLEDEN, C. M., ADAM, H. K., SMITH, R. P. & FITZSIMONS, T. J. The effect of ageing on the disposition of nifedipine and atenolol, 89
SCOTT, M. *see* HARRON, D. W.
SCOTT, S. C. *see* LOCKE-HAYDON, J.
SCULLY, N. *see* THOMAS, M.
SEIDELIN, P. H. *see* MCMURRAY, J.
SELLIAH, K. *see* JAMALUDIN, A.
SEPPÄLÄ, T. *see* MATTILA, M. J.
SESARDIC, D. *see* KOBAYASHI, S.
SESARDIC, D. *see* ZHI-GUANG, T.
SEVER, P. S. *see* OATES, N. S.
SEWELL, H. F. *see* MURRAY, G. I.
SGARAGLI, G. P., NINCI, R., DELLA CORTE, L., VALOTI, M. & PALMI, M. Pharmacokinetics of chlorpromazine (CPZ) and chlorimipramine (CI) in healthy volunteers, 134P
SHAH, K. *see* JACKSON, S. H. D.
SHANKS, R. G. *see* DEERING, A. H.
SHANKS, R. G. *see* HARRON, D. W.
SHANKS, R. G. *see* MCCAFFREY, P. M.
SHANKS, R. G. *see* WHITEHEAD, E. M.
SHARMA, S. K. *see* SILKE, B.
SHARMA, S. K. *see* ZEZULKA, A. V.
SHARPLEY, A. L. *see* SOLOMON, R. A.
SHAYEGAN-SALEK, M. S., LUSCOMBE, D. K., WALKER, S. R., PUGH, S. & VANDENBURG, M. J. Quality of life assessment in patients with angina using the sickness impact profile (SIP), 99P

SHELLY, M. P. *see* MANARA, A. R.
SILAS, J. H. *see* LENNARD, M. S.
SILAS, J. H. *see* MCCOURTY, J. C.
SILKE, B. *see* ZEZULKA, A. V.
SILKE, B., EVANS, J. M., VERMA, S. P., SHARMA, S. K. & TAYLOR, S. H. A new echo-Doppler ultrasound method of cardiac output determination, 147P
SIMMONS, R. *see* BOCHSLER, J. A.
SIMPSON, S. *see* RICHARDS, R.
SINDEBY CULLBERG, M. *see* NYBERG, G.
SINGHVI, S. M., DUCHIN, K. L., MORRISON, R. A., WILLARD, D. A., EVERETT, D. W. & FRANTZ, M. Disposition of fosinopril sodium in healthy subjects, 9
SINZINGER, H., VIRGOLINI, I., FITSCHA, P., RAUSCHA, F. & KALIMAN, J. Stabilization of endothelial lining and decrease in circulating endothelial cells—one mechanism underlying the clinical action of PGE_1?, 775
SIODLAK, M. Z. *see* HOLDING, J. D.
SIX, R. O. *see* DUPONT, A. G.
SMITH, C. L. *see* HILLIER, K.
SMITH, R. *see* RAFFERTY, P.
SMITH, R. L. *see* AYESH, R.
SMITH, R. P. *see* SCOTT, M.
SMITH, S. E. *see* KILBY, P.
SOLOMON, R. A., SHARPLEY, A. L. & COWEN, P. J. 5-HT antagonists and slow wave sleep, 125P
SOLOMON, S. A. *see* WALLER, P. C.
SOMMERS, D. E. K. *see* MEYER, E. C.
SOONS, P. A., DE BOER, A. G., VAN BRUMMELEN, P. & BREIMER, D. D. Pharmacokinetics and dynamics of nitrendipine, and assessment of its oral absorption profile using an osmotic pumping device, 639P
SOPER, C. L. H. *see* HUNTER, K. R.
SPEIRS, C. J. *see* KOBAYASHI, S.
SPINA, E. *see* PISANI, F.
SPRAGG, B. P. *see* HUTCHINGS, A. D.
STACHAK, S. *see* MEHTA, M. U.
STANFORD, C. F. *see* ELBORN, J. S.
STANIFORTH, D. H. & CORBETT, R. To compare the sulphasalazine/sulphapyridine and lactulose/breath hydrogen methods of assessing oro-caecal transit time, 130P
STARK, R. D. *see* COOPER, R. G.
STARZL, T. E. *see* MEHTA, M. U.
STEFFENSEN, G. & PEDERSEN, S. Once nightly sustained release theophylline in elderly subjects—a reply, 524
STEINER, E. *see* EICHELBAUM, M.
STELL, P. M. *see* HOLDING, J. D.
STENTON, S. C., COURT, E. N., HENDRICK, D. J., KELLY, C. A., WALTERS, E. H., GOADBY, P. & KINGSTON, W. P. Loss of platelet activating factor from bronchoalveolar lavage fluid, 117P
STEPHENS, J. *see* BRANDMAN, S.
STEPHENS, M. R. *see* REID, P. G.
STIRLING, F. *see* HORN, C. R.
STIRLING, Y. *see* MEADE, T. W.
STOKES, M. J. *see* COOPER, R. G.
STOKES, T. C. & FEINBERG, G. Blocking of histamine-induced conjunctivitis by the oral antihistamine, astemizole, 771
STONE, T. N. *see* GILMARTIN, J. J.
STOTE, R. M. *see* ZIEMNIAK, J. A.
STRUTHERS, A. D. *see* MCMURRAY, J.
STUBER, H. *see* HANDEL, J.
STULZAFT, D. *see* JONES, A. K. P.
SUER, A. H. *see* WALI, F. A.
SUMNER, D. J., VINCENT, J., ELLIOTT, H. L. & REID, J. L. The chronopharmacology of α-adrenoceptors in man, 103P
SUNZEL, M., PAALZOW, L., BERGGREN, L. & ERIKSSON, I. Respiratory and cardiovascular effects in relation to plasma levels of midazolam and diazepam, 561
SWIRE, F. M. M., MARSDEN, C. A., BARBER, C. & BIRMINGHAM, A. T. Effects of two H_1-receptor antihistamines on event-related potentials (ERPs) and psychomotor performance, 626P
SYRETT, N. *see* BUSH, A.

TAN, P. *see* HOLLAND, R. L.
TAN, S. C. *see* JAMALUDIN, A.
TAOUIS, M. *see* GALITZKY, J.
TASKER, T. *see* BAIRD, A.
TATTERSFIELD, A. E. *see* KNOX, A. J.
TAYLOR, G. W. *see* BLACK, P. N.
TAYLOR, S. H. *see* SILKE, B.
TAYLOR, S. H. *see* ZEZULKA, A. V.
TELEKES, A. *see* HOLLAND, R. L.
TELEKES, A. *see* POSNER, J.
THOMAS, M. *see* MACONOCHIE, J. G.
THOMAS, M., MICHAEL, M. F., ANDREW, P. & SCULLY, N. A study to investigate the effects of raniditine on the metabolic disposition of paracetamol in man, 671P
THOMPSON, A. H., KELMAN, A. W., DE VANE, P. J., HILLIS, W. S. & WHITING, B. Changes in lignocaine disposition in patients with acute ventricular arrhythmias, 150P
THOMSEN, T. *see* DAVIES, B. E.
TOMLINSON, B. *see* WALDEN, R. J.
TRAINA, G. L. *see* BONATI, M.
TSAO, Y. *see* ROBERTS, D. H.
TUCKER, G. T. *see* MCCOURTY, J. C.
TUCKER, G. T. *see* OTTON, S. V.
TURNER, P. *see* AL-SEREITI, M. R.
TURNER, P. *see* DEBRAS, N. M. G.
TWEDDEL, A. C., MARTIN, W., MCGHIE, A. I. & HUTTON, I. Sustained haemodynamic effects of felodipine in patients with chronic cardiac failure, 689

VALOTI, M. *see* SGARAGLI, G. P.
VAN BAAK, M. A., KOENE, F. M. M. & VERSTAPPEN, F. T. J. Exercise haemodynamics and maximal exercise capacity during β-adrenoceptor blockade in normotensive and hypertensive subjects, 169
VAN BRUMMELEN, P. *see* BLAUW, G. J.
VAN BRUMMELEN, P. *see* CHANG, P. C.
VAN BRUMMELEN, P. *see* SOONS, P. A.
VAN BRUMMELEN, P. *see* VAN HARTEN, J.
VANDENBURG, M. *see* BRANDMAN, S.
VANDENBURG, M. J. *see* SHAYEGAN-SALEK, M. S.
VANDENBURG, M. J., KELLY, J. G., WISEMAN, H. T., MANNERING, D., LONG, & GLOVER, D. R. The

effect of lisinopril on digoxin pharmacokinetics in patients with congestive heart failure, 656P
VANDENBURG, M. J. *see* WOODWARD, S. A.
VAN DER KROGT, J. A. *see* CHANG, P. C.
VAN DER NIEPEN, P. *see* DUPONT, A. G.
VAN GULPEN, C. *see* OVERBOSCH, D.
VAN HARTEN, J., VAN BRUMMELEN, P., ZEEGERS, R. R. E. C. M., DANHOF, M. & BREIMER, D. D. The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man, 709
VAN HECKEN, A. *see* ARNOUT, J.
VAN THIEL, D. H. *see* MEHTA, M. U.
VAN ZWIETEN, P. A. *see* BLAUW, G. J.
VEALE, D. *see* GILMARTIN, J. J.
VENKATARAMANAN, R. *see* MEHTA, M. U.
VERMA, S. P. *see* SILKE, B.
VERMA, S. P. *see* ZEZULKA, A. V.
VERMEIJ, P. *see* CHANG, P. C.
VERMEY, P. *see* BLAUW, G. J.
VERMYLEN, J. *see* ARNOUT, J.
VERSTAPPEN, F. T. J. *see* VAN BAAK, M. A.
VILLAR, B. L. B. *see* LOCKE-HAYDON, J.
VINCENT, J. *see* SUMMER, D. J.
VIRGOLINI, I. *see* SINZINGER, H.
VITULO, F. *see* SCARPIGNATO, C.
VOLANS, G. *see* HENRY, J. A.
VORA, J. P. *see* OWENS, D. R.

WADDELL, G. *see* D'HEYGERE, F.
WALDEN, R. J., TOMLINSON, B., GRAHAM, B. R. LIU, J. B. & PRICHARD, B. N. C. The withdrawal syndrome: atenolol and bopindolol in healthy volunteers, 657P
WALI, F. A. & SUER, A. H. Post-tetanic potentiation (PTP) a method of evaluating an intense neuromuscular blockade produced by atracurium in man, 121P
WALKER, R. J. *see* BAILEY, R. R.
WALKER, S. R. *see* PRENTIS, R. A.
WALKER, S. R. *see* SHAYEGAN-SALEK, M. S.
WALLER, D. G. *see* CHALLENOR, V. F.
WALLER, D. G. *see* FRANCIS, J. L.
WALLER, D. G. *see* RENWICK, A. G.
WALLER, D. G. *see* ROBERTSON, D. B. C.
WALLER, P. C. *see* CAMERON, H. A.
WALLER, P. C. *see* HERRICK, A. L.
WALLER, P. C., SOLOMON, S. A. & RAMSAY, L. E. Cigarette smoking and treadmill exercise distances in patients with intermittent claudication: the effect of suggestion, 632P
WALLEY, T. J., HEAGERTY, A. M., WOODS, K. L., BING, R. F., POHL, J. E. F. & BARNETT, D. B. Acute inotropic effects of intravenous nifedipine and its vehicle compared with saline: a double-blind study of systolic time intervals in normal subjects, 187
WALTER, M., LIEBENS, I., GOETHALS, H., RENARD, M., DRESSE, A. & BERNARD, R. Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses, 323
WALTERS, E. H. *see* STENTON, S. C.
WARD, J. W. *see* AYESH, R.
WARD, P. J. *see* BOCHSLER, J. A.
WARING, R. H. *see* AYESH, R.
WARRELL, D. A. *see* EDWARDS, G.
WARRINGTON, S. J. *see* ANKIER, S. I.
WARRINGTON, S. J., ANKIER, S. I. & MEKKI, Q. A. A pharmacokinetic and dynamic study of single nightly doses of conventional and controlled release formulations of trazodone, 110P
WATSON, D. *see* KOBAYASHI, S.
WATT, A. H. *see* REID, P. G.
WATTANAGOON, Y. *see* EDWARDS, G.
WEBER, R. R., MCCOY, C. E., ZIEMNIAK, J. A., FREDERICKSON, D. E., GOLDBERG, L. I. & MURPHY, M. B. Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine$_1$-receptor agonist, in hypertensive patients, 17
WEBSTER, J. *see* ROBB, O. J.
WEBSTER, J. *see* SCOTT, A. K.
WEBSTER, J., WITTE, K. & PETRIE, J. C. Antihypertensive effect of long-acting formulation of nicardipine assessed by clinic and home recordings, 638P
WEIDMAN, K. *see* GILLHAM, R. A.
WEIR, R. J. *see* HERRICK, A. L.
WERNSDORFER, W. H. *see* JAMALUDIN, A.
WESCHE, H. *see* DE MEY, C.
WETZELS, J. F. M., WILTINK, P. G., HOITSMA, A. J., HUYSMANS, F. Th. M. & KOENE, R. A. P. Diuretic and natriuretic effects of nifedipine in healthy persons, 547
WHEELDON, J. *see* CHOONARA, I. A.
WHITEHEAD, E. M. *see* PASSMORE, A. P.
WHITEHEAD, E. M., MCKAIGUE, J. P., RIDDELL, J. G. & SHANKS, R. G. β-adrenoceptor antagonism and cardio-selectivity of dilevalol in man, 637P
WHITESMITH, R. *see* WHYTE, K. F.
WHITING, B. *see* THOMPSON, A. H.
WHITTAM, L. R. *see* RUST, N. D.
WHYTE, K. F., REID, C., ADDIS, G. J., WHITESMITH, R. & REID, J. L. Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline, 571
WIDDOP, B. *see* AYESH, R.
WIKLUND, L. *see* PERSSON, M. P.
WILES, P. G. *see* PULLAR, T.
WILHELMY, J. *see* MÖNIG, H.
WILKES, H. *see* MEADE, T. W.
WILLARD, D. A. *see* SINGHVI, S. M.
WILLARS, J. E. *see* PRICHARD, P. J.
WILLIAMS, A. J. *see* BAIRD, A.
WILLIAMS, B. O. *see* MACPHEE, G. J. A.
WILLIAMS, N. *see* GILLHAM, R. A.
WILSON, D. *see* FERNER, R. E.
WILTINK, P. G. *see* WETZELS, J. F. M.
WINN, M. J. *see* MEADE, T. W.
WISEMAN, H. T. *see* VANDENBURG, M. J.
WISEMAN, L. *see* MACPHEE, G. J. A.
WITTE, K. *see* WEBSTER, J.
WOLFF, J. *see* CLAUSEN, T. G.
WOOD, A. J., BREARLEY, C. J., ARONSON, J. K. & GRAHAME-SMITH, D. G. The effects of salbutamol of *in vivo* cation transport, 624P

WOODHOUSE, K. W. *see* BAILLIE, S. P.
WOODHOUSE, K. W. *see* RODGERS, A.
WOODS, H. S. *see* BAX, N. D. S.
WOODS, H. F. *see* OTTON, S. V.
WOODS, K. L. *see* WALLEY, T. J.
WOODWARD, S. A., ALLEN, S., BOYLE, R., DEWS, I., KIMBER, S., HALLAM, R., RUDORF, J., GLOCKE, M. & VANDENBURG, M. J. A comparison of the effect of carvedilol and nifedipine on the exercise capacity of patients with ischaemic heart disease, 658P
WOOLLARD, R. C. *see* JACKSON, S. H. D.
WRIGHT, N. A. *see* CURRIE, D.
WRIGHT, N. A. *see* NICHOLSON, A. N.
WROE, S. *see* MERCER, A.
WYSE, D. G. Vasoactive responses of a human cystic artery: adrenoceptor characterization, 741

YOUNG, J. *see* ROBB, O. J.
YUEN, K. H. *see* JAMALUDIN, A.

ZECH, P. Y. *see* FERRY, N.
ZEEGERS, R. R. E. C. M. *see* VAN HARTEN, J.
ZETLEIN, M. B. *see* NICHOLSON, A. N.
ZEZULKA, A. V., SILKE, B., VERMA, S. P., SHARMA, S. K. & TAYLOR, S. H. Dose–response effects of nicardipine assessed using an echo-Doppler ultrasound cardiac output device 639P
ZIEMNIAK, J. A., BOPPANA, V. K., CYRONAK, M. J., BECK, T. R., FAMILIAR, R. G., DUBB, J. W., ALLISON, N. L. & STOTE, R. M. Continuous intragastric delivery of fenoldopam: relationship between plasma concentration and effects on renal function, 367
ZIMBARO, G. *see* SCARPIGNATO, C. ZUSSMAN, B. D., CARKSON, A., COATES, P. E. & RAPEPORT, W. G. The pharmacokinetic profile of BRL 43694, a novel 5-HT_3 receptor antagonist, in healthy male volunteers, 107P
ZUSSMAN, B. D. *see* CLARKSON, A.

SUBJECT INDEX

(P = proceedings)

α_1-acid glycoprotein, 514, 733
α-adrenoceptors, 103P, 741
α-adrenoceptor antagonism, 648P
α_2-adrenoceptors, 649P
α_2-adrenoceptor stimulation, 631P
Abbreviated studies, 695
Absorption, 9, 445
Absorption interactions, 229
ACE inhibition, 525, 526
ACE inhibitors, 646P, 719
Acetaldehyde, 213
Acetylation polymorphism, 81, 487
Acetylator status, 585
Acetylisoniazid, 585
Acipimox, 102P
Activated charcoal, 229
Acupuncture, 678P, 679P
Acute pyelonephritis, 223
Acute lymphoblastic leukaemia, 622P
Acute tolerance, 561
Adenosine, 116P, 666P
Adibendan, 655P
Adrenaline, 571
Adverse reactions, 283
Adverse drug reactions, 94P
Age, 133P, 297, 658P
α-hydroxy-midazolam, 457
Aldehyde dehydrogenase, 213
Alfentanil, 108P
Alfuzosin, 417
Alinidine, 154P
Allergy, 381
Allopurinol, 672P, 755
Aminophylline, 645P
5-aminosalicylic acid, 269
Amnesia, 677P
Amodiaquine, 143P
Analgesics, 120P, 628P
Angina, 99P, 153P
Angina pectoris, 640P
Angiotensin II, 90P, 315
Angiotensin converting enzyme, 105P, 533, 646, 719
Antacid, 779
Anterior abdominal wall, 453
Antibiotic, 381, 761
Antibiotics, 527
Antibodies, 381
Anticholinergics, 683
Anticoagulant, 591
Anticonvulsants, 527, 627P
Antidiuresis, 614
Antiemetic, 678P, 679P
Antigen, 626P
Antihistamines, 27
Antihypertensive drugs, 359
Antipyrine, 279, 695
Apis mellifica, 439
Aprotinin, 445
Arrhythmias, 179
Aspirin, 131P
Astemizole, 771
Asthma, 115P, 157, 625P, 667P
Asthmatics, 623P
Atenolol, 67, 124P, 125P, 289, 425, 433, 633P, 657P
Atracurium, 121P
Atrial fibrillation, 101P
Atrial natriuretic peptide, 90P, 630P
Atropine, 27, 647P, 776
Autonomic blockade, 331

β-adrenoceptors, 649P, 660P, 741
β-adrenoceptor antagonism, 637P
β-adrenoceptor antagonist, 124P
β-adrenoceptor antagonists, 125P
β-adrenoceptor blockade, 169, 405
β-adrenoceptor blocker, 179
β-adrenoceptor responses, 625P
β_2-adrenoceptor agonists, 571, 650P
β_2-adrenoceptor antagonist, 433
Baroreceptor function, 417
Basophils, 439
Benzalkonium chloride, 157
Benzodiazepines, 110P, 677P
Benzylpenicillin, 51, 381
Bile, 579
Biliary excretion, 279
Bioassay, 113P
Bioavailability, 261
Bisoprolol, 152P
β-lactam antibiotics, 41
Blood pressure, 561
Body sway, 125P
Bopindolol, 657P
Bradykinin, 105P
Breast milk, 33, 642P
Breath analysis, 213
BRL 24924, 127P
BRL 34915, 114P, 136P
BRL 43694, 106P, 136P
Bromocriptine, 122P, 681P
Bronchial reactivity, 758
Bronchoalveolar lavage fluid, 117P
Bronchoconstriction, 157, 273
Bronchodilation, 683
Bumetanide, 621P
Bupivacaine, 109P
Buprenorphine, 628P
BW 443C, 120P

Caffeine, 134P, 620P
Calcium antagonism, 525
Calcium antagonists, 659P
Calcium carbimide, 213
Calcium channel antagonist, 297

Calcium channel antagonists, 603
Calcium channel blocker, 709, 751
Cancer chemotherapy, 678P
Captopril, 315, 631P, 781, 782
Carbamazepine, 59, 229, 676P
Carbamazepine-10,11-epoxide, 611
Carbimazole, 642P
Carboxymethylcysteine, 664P
Cardiac arrhythmias, 571
Cardiac failure, 165, 635P, 689
Cardiac output, 147P
Cardioselectivity, 637P
Carvedilol, 658P
Cation transport, 624P
Chinese from mainland China, 81
Chlorimipramine, 134P
Chlormethiazole, 766
Chloroquine, 477, 670P
Chlorpromazine, 134P, 680P
Cholecystectomy, 279
Chronopharmacology, 103P
Cicletanine, 359
Cigarette smoking, 632P
Cimetidine, 514, 672P
Circadian variation, 95P
Cirrhosis, 621P
Cisplatin, 137P
Clinical trial, 607
Clotting factor activity, 1
CNS effects, 124P
Colonic absorption, 269
Combination therapy, 349, 425
Committee on Safety of Medicine, 527
Compliance, 145P, 641P
Concentration-effect relationship, 116P
Conjunctivitis, 771
Contractile properties, 405
Cromoglycate, 665P, 666P
Cromokalim, 114P, 136P, 669P
Cuna Amerindians, 75
Cyclic AMP, 725
CV 3988, 445
Cyclopenthiazide, 104P
Cyclosporin, 132P, 401, 402, 509
Cyclosporin absorption, 579
Cytochrome P-450, 465

Dapsone, 81, 487
Debrisoquine, 276, 664P
Debrisoquine metabolic ratio, 141P
Debrisoquine oxidation, 142P
Debrisoquine 4-hydroxylase, 673P, 674P
Degranulation, 439
Denbufylline, 123P
Desipramine, 140P
Desogestrel, 675P
Diazepam, 561, 766
Diclofenac, 628P
Digoxin, 101P, 102P, 138P, 151P, 229, 331, 603, 656P
Dilevalol, 637
Diltiazem, 101P, 599, 660P
Dipipanone, 118P
Diprenorphine, 119P
Dissolution, 139P
Diuretic, 104P, 359
Dobutamine, 55, 654P
Dopa decarboxylase, 195
Dopamine$_1$-receptors, 17
Dopamine, 555, 725
Dopexamine, 555
Doppler echocardiography, 654P
Dosage prediction, 607
Dose-response, 533
Drug distribution, 495
Drug hypersensitivity, 381
Drug interaction, 243, 307, 518
Drug metabolism, 59
Drug monitoring, 138P, 627P

Echocardiography, 331
Echo-Doppler ultrasound, 147P, 639P
Elderly, 94P, 165, 289, 523, 525
Enalapril, 67, 633P, 634P
Enalaprilat, 634P
Enantiomers, 505, 683
Enantioselectivity, 505
Enoxacin, 223
Environmental influence, 95P
Enzyme induction, 140P
Enzyme inhibition, 59
Epidural infusion, 109P
Epilepsy, 59, 676P
Epoprostenol, 341
Epoxide hydrolase, 611
Erythromycin, 401
Ethanol, 123P, 213
Ethnic groups, 776
Event-related potentials, 626P
Exercise, 169
Extrahepatic, 465

Famotidine, 635P
Fatigue, 405
Felodipine, 115P, 689P
Fenoldopam, 17, 367
Fentanyl, 108P
First dose, 276
Flosequinan, 149P, 635P
Flupenthixol, 110P
Flush reaction, 213
Fosinopril sodium, 9
Free water clearance, 547
Frusemide, 229, 547, 621P

GABA, 251
GABA-aminotransferase, 251
Gastric emptying, 108P
Gastric micro-bleeding, 131P
Gastric mucosal bleeding, 131P
Genetic influence, 95P
Genetic polymorphism, 75
Glucose tolerance, 104P
Gludopa, 195, 203
γ-glutamyl-L-dopa, 91P
γ-L-glutamyl-L-dopa, 195, 203
Glyceryl trinitrate, 315

H_1-receptor antagonists, 626P
H_2-receptor antagonist, 111P

Haematocrit, 132P, 509
Haemodialysis, 634P
Haemodynamics, 169, 323, 689
Haemodynamic effects, 709
Hay fever, 623P
Healthy subjects, 375
Heart failure, 323, 646P
Hepatic, 465
Hirsutism, 128P
Histamine, 111P, 114P, 157, 665P, 758, 771
Homeopathic drugs, 439
H.p.l.c. analysis, 136P
5-HT antagonists, 125P, 651P
5-HT_3 receptor antagonist, 106P, 107P
Human artery, 741
Human milk, 495
Human serum, 33
4-hydroxydebrisoquine, 505
5-hydroxytryptamine, 126P
Hypertension, 17, 98P, 103P, 104P, 105P, 136P, 152P, 169, 425, 433, 533, 539, 631P, 633P, 636P, 651P, 652P, 655P, 661P, 719
Hypokalaemia, 571

Ibopamine, 154P
Ibuprofen, 92P, 672P
ICI 118,551, 433
ICI 169,369, 651P
IgE, 381, 439
IgG, 381
IgM, 381
Iloprost, 147P, 148P
Impaired liver function, 96P
Indomethacin, 92P, 118P, 131P, 614, 672P, 755
Inflammatory bowel disease, 129P, 269
Influenza vaccine, 140P
Infusion rate, 709
Innovation, 387
Inotropism, 187
Insulin, 663P
Interaction, 102P, 151P, 397, 401, 527, 656P, 672P
Intermittent claudication, 148P, 631P, 632P, 653P
Intracellular free calcium, 658P
Interocular pressure, 122P, 681P
Intravenous infusion, 187
Intravenous, 264, 457
Intrinsic sympathomimetic activity, 778
Ischaemic heart disease, 146P, 658P
Isometric exercise, 331
Isoniazid, 585

Japanese, 487

Ketanserin, 103P
Ketorolac, 628P
Kidney, 203
Kinetics, 213, 359

L-648,051, 112P
L-652,343, 23
Left ventricular contractility, 331
Leukotriene B_4, 23, 667P
Leukotriene D_4, 111P, 626P
Leukotriene D_4 antagonist, 112P
Lignocaine, 150P
Lipoproteins, 104P
Lisinopril, 307, 533, 634P, 655P, 656P, 719
Lisuride, 122P
Lithium, 91P, 375, 725
Lithium clearance, 547
Liver cirrhosis, 733
Liver function, 96P
Liver microsomes, 643P, 644P
Lung histamine, 439
Lung tumour, 733
LY 171883, 626P
Lymphocytes, 660P

Malaria, 477
Mastitis, 33
Mephenytoin, 75
Metabolism, 9, 213, 701
Metoclopramide, 518, 678P
Metoprolol, 153P, 644P
Midazolam, 140P, 243, 457, 561
Milk albumin, 33
Milk sodium, 33
Minaprine, 680P
Monoacetyldapsone, 81, 487
Monoclonal antibody, 465
Morphine, 133P, 518

Nalbuphine, 264
Nasogastric infusion, 367
Natriuresis, 195, 547, 662P, 725
Nebuliser solutions, 283
Nedocromil, 666P
Neurokinin A, 273
Neuromuscular blockade, 121P
New chemical entity, 387
Nicardipine, 96P, 636P, 638P, 639P
Nicotine, 664P
Nicoumalone, 591
Nifedipine, 187, 289, 297, 307, 397, 425, 547, 599, 621P, 631P, 640P, 658P, 661P, 675P, 701
Nisoldipine, 709, 751
Nitrendipine, 151P, 243, 639P, 662P
Nivaquine, 670P
Nizatidine, 627P
Non-invasive assessment, 647P
Noradrenaline, 649P
Nortriptyline, 140P
Narcotics, 518

Ocular reactivity, 27
Oestrogen 2-hydroxylase, 643P
Omeprazole, 779
Opioid peptide, 120P
Opioid receptor binding, 119P
Oral, 264
Oral administration, 518
Oral contraceptives, 527, 675P
Oro-ceacal transit time, 130P
Osmotic pumping device, 639P
Ouabain, 758
Oxprenolol, 539, 733
Oxyphenonium bromide, 683

Oxytocin, 33

$P_{0.1}$ response, 766
PAF antagonist, 445
Pain, 118P
Paracetamol, 671P
Peripheral arterial disease, 147P
Peritoneal dialysis, 761
Pethidine, 235
Pharmaceutical industry, 387
Pharmacodynamics, 97P, 110P, 120P, 135P, 243, 289, 297, 307, 349, 539, 639P
Pharmacokinetics, 9, 17, 97P, 107P, 110P, 133P, 134P, 136P, 140P, 223, 235, 243, 264, 269, 289, 297, 307, 349, 375, 457, 477, 539, 591, 622P, 634P, 639P, 656P, 695, 701, 709, 755, 761
Phenobarbitone, 145P
Phenotyping method, 81
Phenotype, 585
Phenotypic differences, 505
Phenoxymethylpenicillin, 33
Phenylephrine, 315
Phenylthiourea, 664P
Phosphate, excretion, 614
Physiological model, 235
Physiological tremor, 417
Pimobendane, 323
Pinacidil, 142P
Pindolol, 179
Piroxicam, 614
Pituitary function, 659P
Plasma angiotensin II, 315
Plasma concentration, 367
Plasma concentration-effect relationship, 561
Plasma renin, 315
Platelet activating factor, 117P
Platelet aggregation, 751
Platelets, 658P, 751
Platinum, 137P
Pneumococcus vaccines, 141P
Polymorphism, 142P, 664P, 701
Polymorphonuclear leucocytes, 143P
Population, 701
Portal hypertension, 621P
Post-operative patients, 235
Post-marketing surveillance, 404, 781, 782
Posture, 757
Potassium channel activator, 114P
Polymorphic oxidation, 276
Prazosin, 276
Prednisolone, 622P
Pregnancy, 155P
Premedication, 518
Probenecid, 51, 614
Prolactin, 659P
Propofol, 140P
Propranolol, 67, 98P, 100P, 124P, 125P, 144P, 179, 349, 433, 620P, 636P
Prostaglandins, 129P, 195, 341, 359
Prostaglandin D_2, 23
Prostaglandin D_4, 667P
Prostaglandin E_1, 775
Prostaglandin E_2, 23, 614
Protein binding, 59, 495, 733
Psoriasis, 23
Psychomotor performance, 123P, 626P, 680P
Psychomotor effects, 628P
Psychomotor function, 59
Psychotropic effects, 67
Pulmonary disposition, 235
Pulmonary circulation, 341

Quality of life, 98P, 99P
Quinidine, 97P, 140P, 644P, 673P, 674P, 675P
Quinine, 261, 644P
Quinolones, 223
Quinoneimine, 143P

Radionuclide angiography, 689
Ranitidine, 671P
Raynaud's phenomenon, 751
Rectal, 457
Red cells, 477
Renal blood flow, 555
Renal effects, 90P, 92P
Renal failure, 719, 761
Renal function, 93P, 599
Renal insufficiency, 359
Renal plasma flow, 367
Renal response, 91P
Renal transplant, 509
Renin, 195, 203, 315, 725
Renal failure, 634P
Research and development, 387
Resins, 229
Respiratory muscle strength, 766
Rest and exercise, 689
REV 5901, 111P
Ritodrine, 155P

Salbutamol, 115P, 624P, 625P, 667P
Salicylate, 95P
Salivary secretion, 27
Salmeterol, 115P
Salt restriction, 92P
Saturation kinetics, 41
Sedation, 417
Selectivity, 650P
Self-poisoning, 120P
Semen, 144P
Serotonin, 629P
Sickness impact profile, 99P
SK&F 86466, 648P
SK&F 100168, 154P
Skin blood flow, 631P
Sleep, 125P
Slow release, 95P, 97P, 133P, 139P
Sodium excretion, 614
Sodium reabsorption, 90P
Sodium valproate, 59
Soluble human insulin, 453
Sperm motility, 620P
Spironolactone, 128P
SQ 27,519, 9
Stereospecific assay, 591
Stereospecific pharmacokinetics, 669P
Substance P, 273
Success rate, 387

(+)-sulpiride, 203
D-sulpiride, 90P
Sulpiride, 668P
Sustained release, 97P, 100P, 131P, 139P, 640P, 645P
Systolic time intervals, 187, 331

T-tube ligation, 579
Tachykinins, 273
Teicoplanin, 761
Tenoxicam, 93P
Terfenadine, 623P
Terguride, 122P
Theophylline, 95P, 134P, 397, 523, 525, 571, 642P, 757
Thigh, 453
Thiopentone, 140P
Thyroid function, 642P
Timolol, 681P
Toxicity, 477
Trazodone, 110P, 135P
Tremor, 417
Trimethylaminuria, 664P
Trimethylamine oxidation, 142P
Trimodal distribution, 487
Tubular excretion, 51
Tumours, 137P
Tyramine, 154P

UD-CG 212, 323
Urinary tract infection, 223

Valpromide, 611
Valsalva's manoeuvre, 315
Vasodilation, 273
Vasodilator agents, 341
Vasodilator, 149P
Vasopressin, 621P
Ventilatory response, 766
Ventricular arrhythmias, 150P
Verapamil, 97P, 98P, 100P, 101P, 349, 397, 402, 599, 659P
Vigabatrin, 251
Vitamin K_1, 1
Volunteers, 681P

Warfarin, 1, 131P, 145P, 146P, 607
Whole body plethysmography, 113P

Xamoterol, 165
Yellow cards, 527
Yohimbine, 649P
Young, 289